

Review Article

Modern Principles of Diagnosis and Treatment in Complex Regional Pain Syndrome

Alexandra Melf-Marzi, Bettina Böhringer, Matthias Wiehle, Constanze Hausteiner-Wiehle

Department for BG Rehabilitation; Out-patient CRPS Clinic; BG Trauma Center Murnau; Alexandra Melf-Marzi

Department for Anesthesiology, Intensive Care Medicine and Pain Therapy; Multimodal Pain Therapy; BG Trauma Center Murnau; Dr. med. Bettina Böhringer

Department for Neurology, Clinical Neurophysiology and Stroke Unit; BG Trauma Center Murnau; Dr. med. Matthias Wiehle, Prof. Dr. med. Constanze Hausteiner-Wiehle

Clinic and Polyclinic for Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich; Prof. Dr. med. Constanze Hausteiner-Wiehle

Summary

Background: Complex regional pain syndrome (CRPS) is a relatively common complication, occurring in 5% of cases after injury or surgery, particularly in the limbs. The incidence of CRPS is around 5–26/100 000. The latest revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-11) now categorizes CRPS as a primary pain condition of multifactorial origin, rather than a disease of the skeletal system or the autonomic nervous system.

Method: Based on a selective search of the literature, we summarize current principles for the diagnosis and treatment of CRPS.

Results: Regional findings in CRPS are accompanied by systemic symptoms, especially by neurocognitive disorders of body perception and of symptom processing. The therapeutic focus is shifting from predominantly passive peripheral measures to early active treatments acting both centrally and peripherally. The treatment is centered on physiotherapy and occupational therapy to improve sensory perception, strength, (fine) motor skills, and sensorimotor integration/ body perception. This is supported by stepped psychological interventions to reduce anxiety and avoidance behavior, medication to decrease inflammation and pain, passive physical measures for reduction of edema and of pain, and medical aids to improve functioning in daily life. Interventional procedures should be limited to exceptional cases and only be performed in specialized centers. Spinal cord and dorsal root ganglion stimulation, respectively, are the interventions with the best evidence.

Conclusion: The modern principles for the diagnosis and treatment of CRPS consider both, physiological and psychological mechanisms, with the primary goal of restoring function and participation. More research is needed to strengthen the evidence base in this field.

Cite this as:

Melf-Marzi A, Böhringer B, Wiehle M, Hausteiner-Wiehle C: Modern Principles of Diagnosis and Treatment in Complex Regional Pain Syndrome *Dtsch Arztebl Int* 2022; 119: 879–86. DOI: 10.3238/arztebl.m2022.0358

In 1994, after a number of previous different historical terms (e1–e10), complex regional pain syndrome (CRPS) was conceptualized for the first time by the “International Association for the Study of Pain” (IASP) (e10). Consensus criteria were established ten years later. They were revised in 2010 and slightly adapted in 2021 (*Box 1*) (1, 2).

The penultimate revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-9) had still classified essentially identical clinical conditions as “sympathetic reflex dystrophy” or “algoneurodystrophy”. On the one hand, ICD-10 mentions “neurodystrophy/algodystrophy” (which included sympathetic reflex dystrophy, Sudeck’s bone atrophy, shoulder-hand syndrome), while using the term “causalgia” if it developed after a nerve injury. In 2019, the term CRPS was included in the ICD-10. A distinction was made between Type 1 without nerve injury and Type 2 with nerve injury. Only shoulder-hand syndrome remained as “neurodystrophy/algodystrophy”.

On 1 December 2022, ICD-11 came into effect and is meanwhile also available as a German draft version

cme plus +

This article has been certified by the North Rhine Academy for Continuing Medical Education. Participation in the CME certification program is possible only over the internet: cme.aerzteblatt.de. The deadline for submission is 26 December 2023.

BOX 1

Budapest criteria

1. Continuing pain, which is disproportionate to any inciting event
2. The patient must report at least one symptom in three of the four following categories:
 - a) sensory: hyperalgesia (increased sensitivity to pain stimuli); hyperesthesia (increased sensitivity to light touch, allodynia)
 - b) vasomotor: skin temperature asymmetry; changes or asymmetry of skin color
 - c) sudomotor: changes or asymmetry of local sweating; edema
 - d) motor/trophic: decreased range of motion; motor dysfunction (weakness, dystonia, tremor); trophic changes (hair or nail growth, skin)
3. The patient must display at least one sign in two or more of the four following categories at the time of the examination:
 - a) sensory: hyperalgesia to sharp stimuli (e.g., toothpick); allodynia (evoked by light touch / brushstroke; pain on deep somatic pressure to joints/bones/muscles, with joint movement)
 - b) vasomotor: skin temperature asymmetry; changes or asymmetry of skin color
 - c) sudomotor: changes or asymmetry of local sweating; edema
 - d) motor/trophic: decreased range of motion; motor dysfunction (weakness, dystonia, tremor); trophic changes (hair or nail growth, skin)
4. There is no other diagnosis that better explains the signs and symptoms.

(3, 4). It assigns both CRPS types and, for the first time, shoulder-hand syndrome together to a new symptom category—with a cross reference to chronic postoperative/post-traumatic pain (3, 4). “Chronic primary pain” now comprises, in addition to CRPS, other regional and widespread pain syndromes, such as chronic widespread pain/fibromyalgia syndrome, chronic primary low back pain, chronic primary visceral pain, and chronic primary headache. Common features, such as persistency, high emotional burden, and significant functional limitations are highlighted (2–4, e11). Chronic primary pain is referred to as “multifactorial” and sometimes as “nociplastic”, as opposed to nociceptive (thermic, mechanical) pain and neuropathic (nerve injury) pain (3, 4, e11–e14). “Nociplastic” is understood as a potentially reversible central hypersensitivity to stimuli without tissue or nerve damage (e12–e20). Indeed, the mechanisms of developing CRPS are nowadays assumed primarily to be peripheral, spinal, and cerebral sensitization processes due to neurogenic inflammatory (auto-)immune response, autonomic dysregulation, and maladaptive protective behavior (learned disuse) (5–14, e15, e21–e25).

What are the implications of the new ICD-11 conceptual framework for clinical practical diagnostic and therapeutic strategies for CRPS?

Methods

The present review article takes a clinical interdisciplinary view of new diagnostic aspects and function-focused forms of treatment of CRPS. It follows the current German (15) and international CRPS guidelines and expert recommendations (16–18). A selective literature search was also conducted in PubMed for original articles and reviews published in English or German relating to the clinical presentation, course, (differential) diagnostics, and treatment of CRPS in adults. The search terms were “CPRS”, “complex regional pain syndrome”, “diagnosis”, “treatment”, “guideline”, “consensus”, and “recommendation”. The clinically most useful articles are cited directly, and a list of further reading is provided as e-references.

Diagnosis

Incidence, inciting causes, risk factors

The incidence of CRPS is between 5 and 26 per 100 000 per year, its prevalence is about 20/100 000 (19, 20); numbers fluctuate strongly, depending on diagnostic criteria (8, 19, 20). Women are more commonly affected than men, with a ratio of 2–4 : 1 (19–21, e26–e28). The age peak is around the 40th to 70th year of life (19–21, e26–e28). However, CRPS occurs at any age, also affecting children and adolescents at a rate of about 1 to 5 per 100 000 (19–21, e26, e27, e29, e30).

In 0.2 to 9% of cases, CRPS develops after peripheral fractures or ligament injuries, in 2 to 5% after nerve injury, and in 1 to 13% after surgery of the extremities (8, e22–e25, e28, e31–e39). On the other hand, 40 to 50% of all CRPS cases are preceded by fractures, and 30 to 40% are the result of other injuries or surgical procedures (1, 8, 19–21, e26, e27). Type and degree of tissue or nerve damage, immobilization, and high initial pain intensity increase the risk of developing CRPS (Box 2) (e28, e34–e42). Yet even mild tissue injury can result in CRPS, for example, following arthroscopy, tourniquet application, snowball injury, injection, vaccination, or local infection (19, 20, e26, e27, e43–e45). CRPS of the limbs (e.g., shoulder-hand syndrome) can also follow cerebral, spinal, and cardiac ischemia, degeneration, injuries, surgical procedures and, in isolated cases, malignant neoplasm, even though the tissue injury may lie far proximal to the site of manifestation (20, e27, e41, e46–e52, e45–e51). No initial event is clearly defined in about three to ten percent of cases (19–21, e27, e53). Painful pre-existing conditions (e54–e57) and stressful life events (6, 22, e58, e59), even without tissue injury (6), can precede CRPS (Box 2).

There is conflicting data on psychological risk factors for developing CRPS. Overall, the rate of pre-morbid and comorbid post-traumatic stress disorders (PTSD) appears to be increased: 27 to 38% fulfill all, 56% most criteria (22, e59). Anxiousness and pain catastrophizing appear to both increase the risk of disease (e60) and worsen its prognosis (e61–e63). Most studies, however, do not show an increased rate

of depression, anxiety disorders, or personality disorders as compared with other diseases (22, e33, e37, e42, e57–e66) (*Box 2*).

Clinical presentations and diagnostic criteria

The cardinal symptoms of CRPS are regional pain and other sensory, motor, autonomic, and trophic disturbances (*Box 1*). Distal extremities are by far the most common sites of manifestation of CRPS, with the hands being affected more often than the feet. The symptoms have a “glove-” or “sock-like” distribution and do not correspond to a dermatome or area of innervation. There have been isolated reports of CRPS affecting, amongst other sites, the face and trunk (e45, e67–e69).

To establish a CRPS diagnosis, the Budapest criteria must be met—as per the current guidelines, too (*Box 1*) (1–4, 15–18). Their sensitivity is around 98 to 99%, their specificity about 36 to 68% (1, 8, e46, e57). The entry criterion is continuing pain disproportionate to any inciting event (in 1994 it was still “harmful event or immobilization” [e10]). Neither the disproportionality nor the potential inciting cause is defined more precisely. No other disorder, including the primary injury, better explains the signs and symptoms (1, 15–18). There is no time criteria; the CRPS guideline of the German Neurological Society (DGN) specifies two to three months as a reasonable time point (15) by which all criteria must be fulfilled, bearing in mind that the healing process of the primary injury still needs to be awaited.

The majority of patients present other symptoms, in particular top-down disturbances of body perception and symptom processing (7–12, 15–17, 22, 23, e70–e108) (*Box 3*). For example, between 32 and 84% have neuropsychological symptoms relating to the affected limb, i.e., disturbances of alertness/attentiveness, sense of body ownership/sense of position, experience of authorship/control of actions, and attribution of meaning/emotions (7, 23, e69–e81), even in the form of depersonalization (e82) or alexithymia, i.e., a reduced ability to identify emotions experienced by themselves and others (e83). A combination of finger misperception and body image disturbance differentiated between patients with CRPS and those with fractures with a specificity of 85% and a positive predictive value of 84% (e84).

There appear to be clinical, possibly pathophysiological, overlaps with neuropathic pain syndromes (15–18, e101–e103), as well as with other chronic primary pain syndromes (3, 4, 18, e11–e14, e104–e108) and functional (e18), (especially functional neurological) disorders, defined as involuntary discontinuity of the normal integration of motor, sensory, cognitive functions (7, 9, 11, 12, e109–e114), and PTSD (6, 22, e59, e80). Modern guidelines recommend assessing affective disturbances and body perception disturbances, especially post-traumatic stress symptoms, attentional disturbances, fear of touch or of movement (15–18). So far, however, such features have not been included in any diagnostic criteria (1–4) (*Box 3*).

BOX 2

Potential risk factors for developing CRPS

- female sex, in particular postmenopausal women (women of middle age also sustain fractures three times more often than men)
- severe injuries, in particular crush injuries, displaced, juxta-articular or intra-articular fractures (especially distal radius fractures); ankle injuries; nerve injuries; prolonged anesthesia/ischemia, manipulation procedures such as secondary fracture reductions; restricted range of motion and functional impairment, prolonged immobilization
- high pain intensity initially or directly after surgery, sensory disturbances and low skin temperature (for example, persistent pain ≥ 5 on a numerical rating scale of 10 points for more than a week after conservative treatment of a distal radius fracture)
- chronic or widespread pain and hypersensitivity, such as migraine, fibromyalgia, back/period pain, neuropathies, osteoporosis, osteoarthritis, rheumatoid arthritis; also, asthma/allergies
- high anxiety level, depressiveness, passivity, avoidance tendency, pain catastrophizing, or manifest disorders associated with anxiety and trauma/stress; previous critical life events; desire for compensation and litigation

Technical and laboratory findings are not included in the diagnostic criteria either (1–4): CRPS is and remains a clinical diagnosis. If history and clinical examination have established the diagnosis, then no guideline recommends any further diagnostic investigations (15–18). To help substantiate the diagnosis, the DGN CRPS guideline recommends a three-phase bone scan only during the first year of disease in cases of doubt or if an expert opinion is required in the foreseeable future (15). Additional diagnostic investigations, however, allow sound differential diagnostics in accordance with the 4th Budapest criterion (*eBox*) (15, 16, 18, e115–126).

Subtypes, clinical course, prognosis

Differentiation between CRPS 1 and 2 is controversial, given that, clinically, there is no difference (2, 8, 15–18, e28). Modern guidelines do not express any difference in recommendations between the two (15–18). The distinction between “warm” and “cold” CRPS subtypes or stages, however, is of some clinical relevance with regard to treatment (see below) (8, 15, 17, e127–e129). The “warm” subtype is often described as “red”, “sweaty”, and “early”. The “cold” subtype is characterized as “blue”, “dystrophic/atrophic”, “late” and regarded as having a less favorable prognosis. Depending on the situation, vasomotor and sudomotor symptoms, such as skin color changes and sweating, may fluctuate (2–4, 10, 13) as an indication of central neurogenic regulation – there is possibly a peripheral inflammatory etiology behind “warm” CRPS signs and symptoms, while “cold” CRPS is of a central nervous nociplastic origin (13, e21). The DGN CRPS guideline refers to acute (less than 6 months) as opposed to chronic CRPS (15), while current US-American and British

BOX 3

Additional clinical findings in CRPS

Allodynia

- pain on light movement/touch/pressure (e.g., draught, brush, finger [pressure less than 100 g/cm² or load less than 500 g])
- pain from vibration (e.g. tuning fork on a bony prominence), cold, heat

Hyperalgesia

- periarticular pressure hyperalgesia distal to the site of injury/surgery
- solitary sharp stimulus (pinprick) is felt stronger/longer

Disturbance of body perception/interoception

- attention: exerted, hypervigilant focussing or disregarding (neglect-like/dissociation)
- shape, size, weight, position, posture, laterality, symmetry, ownership, e.g., as if limbs were detached, foreign, dead (“as if wooden”, “like part of a dead body”)
- attribution of meaning or affective evaluation, e.g., threatening, disgusting, or hated limb; caution: desire for amputation

(Functional) disturbances of voluntary motor function

- protective posture, slowed, reduced or non-movement
- reduced experience of motor action, control, intention (agency)
- weakness, disturbances of fine motor skills, coordination or movement
- sometimes several types of disturbance in one and the same limb, e.g.
 - myoclonus or tremor (with “entrainment”, i.e. unconscious synchronization with rhythmic movements of the unaffected limb)
 - dystonia (usually in fixed flexion/supination)
- increase during manipulation, decrease when distracted, no decrease with sensory tricks (“gestes antagonistes”)

Trophic, vasomotor and sudomotor disturbances

- non-pitting edema (circumference measurements where possible)
- skin color usually reddish-blue, with time more waxy-pale (skin care?)
- skin temperature about 1–2 degrees difference to the contralateral side
- hair growth: usually increased, thick, dark, sometimes reduced, finer hair (shaved?)
- nail growth: usually harder, brittle, faster or slower nail growth (nail care?)
- increased, with time reduced, sweating
- trophic skin lesions or pressure lesions (rarely: differential diagnosis self-harm)

Tendency to spread and become generalized

- at times tendency to spread proximally or to other limbs
- other pain sites: contralateral and generalized reduced pain threshold/body image disturbance
- sensitivity to noise, light, smell, touch, at times with autonomic arousal
- cardiovascular dysregulation, increased heart rate, reduced heart rate variability
- micturition and digestive problems

Affective, cognitive, general signs and symptoms; behavioral changes

- fear, particularly of touch, movement, and disease progression
- avoidance of sensory stimuli from clothes, wind, movement, other people, etc.
- signs and symptoms of trauma-related disorders (helplessness, flashbacks, dissociation, depersonalization, avoidance, hypervigilance/hyperarousal)
- mood fluctuations, depressiveness, alexithymia (reduced awareness of one's own emotions and those of others), withdrawal
- fatigue, sleeping problems, and cognitive disturbances

recommendations distinguish between early (less than 18 months) and persistent CRPS (18). New CRPS subtypes (“CRPS with remission of some features” and “not otherwise specified”) were proposed for subsyndromal courses which no longer fully meet the diagnostic criteria or never have (2).

CRPS usually settles within three to 13 months, sometimes even without treatment (20, 21, 24, e28, e74, e130, e131). Complete remissions are rare, though, and difficult to define (21, 24, e132). In more than one half of adult patients at least some of the signs and symptoms persist, especially pain and motor symptoms (20, 24, e28, e74, e130). Although most patients return to work, one third require work-

place adaptations, and one third remain permanently unfit for work (20, 24, e74, e130). In about 7%, the CRPS spreads to involve other limbs without any further traumatic event (2, 16, 17, e74, e133, e134).

Differential diagnostic challenges

The differential diagnosis of CRPS is wide-ranging, which inevitably carries with it the risk of being missed or even becoming subject to diagnostic inflation or a diagnosis of convenience (*Table 1*) (15–17, 20, 25, e135). Findings are sometimes difficult to objectify, resulting in discrepancies between history and examination as well as between one examination situation to another (2, 15–18, 25, e136). The fact that the CRPS diagnostic criteria demand that the pain should be disproportionate to the inciting event can lead to it being wrongly attributed to trivial trauma (11). Focus is therefore on a detailed history, clinical examination, and differential diagnostic considerations from an interdisciplinary perspective, together with a careful assessment of the primary injury and repeated (photographic) documentation (2, 15–18, 25). The Budapest criteria are assessed in comparison with the healthy side, paying due respect to risk factors and additional symptoms (*Box 1, Box 3*).

A particular distinction must be made from rheumatic, vascular/vasomotor, infectious, (functional) neurological, psychosomatic/psychiatric disorders, and complications from previous treatment (*Table 1*) (11, 15–17, 20, 25, e23–25, e110–e114, e135–e142). The longer CRPS has been present, the more difficult is the differentiation from chronic non-use/underuse of other origin (15). Referral to an interdisciplinary center should be arranged if there are any doubts, complications (symptom spread, fixed dystonia, skin lesions/infections, malignant edema, severe psychological burden, desire for amputation), or no improvement after about two months (15–18) (*Table 1*).

Examinations in the medicolegal setting reveal high rates of simulation, somatoform/functional disorders, opioid dependency (e143–e145), as well as deterioration of signs and symptoms instead of improvement over time (e136). For the purposes of an expert opinion with near complete proof of causality, the diagnosis of CRPS is often insufficient: The German pain assessment guideline refers to CRPS as an “extraordinary chronic pain syndrome” and a “special case”, and rejects trivial trauma as a negligible and interchangeable cause (e135, e146). For confirmation of a comprehensible causal relationship, it demands a (contentiously early) onset of symptoms within a few days to two weeks after the inciting event.

Treatment

Treatment is centered around an inflammatory and particularly sensitive acute phase and an early and late rehabilitation (*Table 2*) (15–18, e147). Prior to that, it is worth considering prevention even before CRPS becomes manifest. The key therapeutic principle is functional restoration, guided by graded occupational

TABLE 1

Subspecialties involved in interdisciplinary clinical diagnostic workup of complex regional pain syndrome (CRPS)

Specialty	Main issues	Differential diagnoses or comorbid diagnoses relevant for the further clinical course (selection)
Trauma/hand/foot surgery, possibly vascular surgery	<ul style="list-style-type: none"> ● CRPS-related or independent structural damage ● indication for surgical intervention 	<ul style="list-style-type: none"> ● osteoarthritis, arthritis, ligament injury, (unstable) fracture, non-union ● soft-tissue infection, compression syndrome, thrombosis, vasculitis, erythromelalgia, lipedema/lymphedema ● plate break, foreign body, factitious manipulation (ligature mark? frostbite?)
Neurology, possibly neurosurgery	<ul style="list-style-type: none"> ● (differential) diagnostics of peripheral nerves ● differentiated assessment of sensorimotor function ● pain differentiation ● consider cerebral imaging and functional diagnostics ● pharmacological, or possibly interventional, treatment 	<ul style="list-style-type: none"> ● peripheral nerve/plexus injury, mono/polyneuropathy ● neuralgic shoulder amyotrophy, syringomyelia, neuroborreliosis, post-zoster neuralgia ● neuroma, glomus tumor ● central thalamic pain ● motor dysfunction, e.g. focal dystonia, Parkinson's syndrome ● functional neurological disorder, including clenched fist syndrome^{*1}
Pain therapy, possibly rheumatology	<ul style="list-style-type: none"> ● pain differentiation (local, regional, widespread, nociceptive, neuropathic, nociplastic) ● chronification risks, substance abuse, resources ● pharmacological, or possibly interventional, treatment 	<ul style="list-style-type: none"> ● generalized pain disorder, e.g., fibromyalgia syndrome, rheumatism ● comorbid/pre-existing pain disorder, e.g. migraine ● drug dependence or opioid-induced hyperalgesia
Clinical psychology, psychosomatics, psychiatry, psychological or medical psychotherapy	<ul style="list-style-type: none"> ● psychological symptoms/comorbidity ● context factors (above all psychosocial burden, identification with the sick role, resources) 	<ul style="list-style-type: none"> ● functional/dissociative/somatiform (ICD-11: bodily distress) disorder^{*2} ● self-harm, factitious disorder^{*3}, e.g. Secretan's syndrome^{*4} ● body integrity identity disorder^{*5} ● anxiety/post-traumatic stress disorder, depression ● suicidal tendencies
Rehabilitation medicine, occupational therapy, and physiotherapy	<ul style="list-style-type: none"> ● range of motion/flexibility and limb use ● self-care ability and ability to work 	<ul style="list-style-type: none"> ● non-physiological movement patterns ● sensorimotor or body perception disturbances ● inactivity atrophy, joint stiffness ● deconditioning or muscle imbalance, even beyond the CRPS region itself ● activities of daily living and functional capacity ● distinction from aggravation/simulation/dissimulation

*1 usually painful, tightly clenched fingers with no vaso- or sudomotor changes

*2 continuing pain, sensory or motor disorders, without or with only slight vaso- or sudomotor changes, yet with underuse, psychosocial burden, and dysfunctional attention/expectations/behavior (numerous overlaps with functional neurological disorders)

*3 e.g., constrained postures; manipulations such as ligature marks, hypothermia, discoloration; desire for amputation

*4 from blows (e.g., against the wall, table edge; known as wall-banging) resulting in inflammatory, often bluish, edematous, peritendinous fibrosis extending from the dorsum of the hand to the wrist

*5 desire for a physical disability, often dating back to the teens, and often associated with body image disturbance and desire for amputation

therapy and physiotherapy—Harden et al. (18) even spoke of “reanimation”. This is facilitated by psychological, physical, pharmacological, and, in individual cases, invasive pain management (15–18). The primary therapeutic goal is a lasting improvement of function and participation. With this in mind, chances and risks of all therapeutic measures must be weighed up against each other. Possible barriers to recovery, including iatrogenic issues, must be taken into account (15–18). Throughout every phase of treatment, all passive, fear or pain amplifying, and movement restricting measures against the patient’s will or outside the patient’s control, including unannounced touching and nocebo messages, are contraindicated (15–18).

Prevention

Of central importance are as little tissue traumatization and immobilization as possible, adequate pain relief, and detailed information for the patient with regard to

normal findings and ranges of movement (*Table 2*) (8, 15–18, e23–25, e125, e148–e154). The incidence of CRPS after radius fractures appears to fall if patients are taught light range-of-motion exercises early on (e153); physiotherapy and occupational therapy, together with explicit motor imagery (see below), appear to reduce pain and improve function (e154). There is some controversy concerning any preventive anti-inflammatory effect of ascorbic acid (16–18, e155, e156); this agent does not find mention in the DGN CRPS guideline (15).

The treatment of manifest CRPS

Treatments are usually delivered within individually tailored, multimodal programs that have been shown to be effective (15–18, 26–28, e23–e25, e146, e157–e162). Available data supporting specific individual interventions (see below) are insufficient, comprising only a few randomized controlled trials, mostly

TABLE 2

Principles of staged treatment of complex regional pain syndrome (CRPS)

Strategy	Examples
Primary and secondary prevention	
<ul style="list-style-type: none"> ● as little tissue traumatization and immobilization as possible ● psychoeducation with a reassuring and activity-orientated approach ● good post-traumatic or peri-/postoperative analgesia 	<ul style="list-style-type: none"> ● avoid unnecessary invasive operative techniques, repeated fracture reductions and restrictive, malpositioned immobilization ● encourage and provide guidance for early use, e.g. "It is good for the healing process if you touch and move your fingers; I'll show you how to do it." ● explain transient, physiological signs of injury/immobilization*, e.g., "temporary pain, swelling, sensitivity to touch, sometimes even slightly increased hair growth, often develop after such disorders / injuries / operations and usually settle quite soon." ● monitor closely, especially in the presence of risk factors
Acute phase and early rehabilitation	
<ul style="list-style-type: none"> ● Instructions on using and reintegrating the limb ● Symptomatic therapy <p>In particular, passive measures must not interfere with function and participation.</p>	<ul style="list-style-type: none"> ● early, active physiotherapy and occupational therapy together with identification and reduction of dysfunctional movement patterns, fears and avoidance behavior ● integration of playful and distracting exercises at home, relevant to everyday life, e.g. by using MindMotion GO, Orientate app, Recognize app ● integration of imagination, relaxation, hypnosis, learning, biofeedback, distraction and acceptance and commitment techniques ● tolerable physical measures, such as contrast baths /carbonic acid baths, heat and cold application, electrotherapy/transcutaneous electrical nerve stimulation (TENS), acupuncture ● early anti-inflammatory drug therapy and individually tailored analgesic pharmacotherapy ● medical aids: e.g. flat-knit custom-made compression gloves and stockings (class 1), (night) positioning splint, functional or, possibly, gentle static/dynamic correction splint (e.g. Moberg); crutches, wheelchair ● consider supplementary options such as concentrative movement therapy, Feldenkrais method, yoga, Tai-Chi, aerobic exercise, aquatic physiotherapy, pacing, sleep hygiene
Late rehabilitation and reintegration	
<ul style="list-style-type: none"> ● Promote autonomy and participation ● Use individual resources, consider individual barriers to recovery 	<ul style="list-style-type: none"> ● assess and support social and vocational rehabilitation or home/workplace modifications ● realistic information about pension/compensation claims; consider whether short-term or partial disability pension might be better than a full disability pension ● in cases of treatment stagnation/setback: <ul style="list-style-type: none"> – consider widening assessment of findings and differential diagnoses – guideline-based treatment of somatic and mental comorbidities – identification of conflicting goals, consider developing alternatives to the sick role

* dolor, associated also with allodynia/hyperalgesia, tumor, rubor, calor, functio laesa, occasionally also trophic changes such as excessive hair growth or disuse osteopenia

involving small or (considering the low specificity of diagnostic criteria) heterogeneous populations (Table 2).

Active forms of treatment

Physiotherapy and occupational therapy

The key recommendation of current guidelines throughout all treatment phases is physiotherapy and occupational therapy, together with neurocognitive elements or components of behavioral therapy aiming at the normalization of sensorimotor integration. This is achieved by graded exposure to strength and movement as well as visuo-tactile stimulation and discrimination (Table 2) (8, 15–18, 29–31, e23–e25, e163–e185):

- The Perfetti method and graded motor imagery are directed towards cortical reorganization by means of left-right discrimination training (recognizing photos of

limbs in different positions of function), explicit motor imagery, and mirror therapy (projecting the healthy, positively connotated limb onto the affected side) (8, 15–18, 29–31, e23–e25, e80, e163–e172). The patient is introduced as early as possible to individual leisure activities/work requirements by self-exercises, also with the help of computer applications (e173–e181). Mirror therapy appears to be particularly effective for post-stroke CRPS (15, 29 e168), but it is not sufficient on its own for the majority of cases. Indeed, mirror therapy can even make individual cases worse, or result in the development of symptoms on the contralateral side, (15, 29, e169). Overall, neurocognitive procedures appear to improve function more than alleviate pain (27, 29, e169).

- There is adequate proof that graded exposure can improve function, pain, and fear (15–18, 26, e182).

Perceptual disturbances, kinesiophobia and dysfunctional protective behavior are addressed and gradually reduced by graded exposure and the violation of dysfunctional expectations. In such an approach, occupational therapy, physiotherapy and psychology work closely together.

Pain exposure without psychological support is a subject of controversy because of frequent discontinuations of treatment; therefore, it is no longer recommended (15, 18, 26, 31). Self-efficacy, fitness and body-mind techniques, integrated into an overall treatment concept which includes playful or meditative methods, often in groups, can additionally improve body perception and control in a cost-effective way with few side effects (Table 2, 16, 17, 26, e24). Studies dealing with this, however, are lacking.

Psychological treatment

Current guidelines recommend stepped psychological interventions (Table 2) (15–18):

- Teaching a biopsychosocial explanatory model which provides motivation and instructions for the best possible active and fear-free use of the limb (psychoeducation) is conducted immediately by the attending “somatic” healthcare staff (15–18, e152, e153). For this purpose, patients need information, repeated often and in reassuring, layman’s language, which they can then put into action.
- Within the framework of multimodal treatment, clinical psychologists conduct a more differentiated form of psychological pain therapy, oriented predominantly towards cognitive behavioral therapy and often also in groups to enable exchange with fellow patients (15–18).
- Guideline-based psychotherapy provided by board-certified medical/psychological psychotherapists may be indicated for intractable cases and patients with considerable biographical or current stresses and strains and/or mental comorbidity (15–18).

However, the level of evidence covering psychoeducative/psychological and, above all, psychotherapeutic interventions for CRPS is low and for the most part derived from other chronic pain disorders (8, 15–18, 34, e23–e25, e159, e186–e192).

Passive forms of treatment

Medication

The focus of pharmacotherapy (eTable 1) is also primarily on maintaining function (15–18): Sedatives, for example, improve tension and sleep disturbances, yet interfere with treatment cooperation and participation (fitness to drive!). It is important to inform patients in detail about risks/side effects, the need to gradually increase the dose until adequate levels are reached, to consider a possible delayed, sometimes absent, effect, and to discontinue or withdraw if necessary (15–18, 34, e193). Medication needs decrease and self-efficacy improves by incorporating active, non-pharmacological interventions such as relaxation methods.

Pharmacotherapy is based almost without exception on off-label drugs where evidence is limited (eTable 1) (8, 15–18, 26–28, 32, e23–e25, e194–e209). Current treatment recommendations vary: The German guideline recommends anti-inflammatory bis-phosphonates and steroids which are of equal value for the acute inflammatory phase (15), the British guideline recommends only bisphosphonates (16), while the position paper of the European Pain Federation recommends neither (17). The DGN CRPS guideline regards oral pain pharmacotherapy as a basic measure (15) and recommends gabapentinoids with some reservations and ketamine with strict indications (15). Other guidelines are more cautious and recommend prescribing analgesics only when stopping rules are established due to their frequent ineffectiveness and side effects (17) or only when functional restoration is not possible without them (18). Beyond that, many guidelines refer to the more established treatment recommendations that exist for neuropathic pain (for example, the use of gabapentinoids, antidepressants, possibly botulinum toxin, 15–17, 33, e209), although even CRPS 2 only partially meets the definition of neuropathic pain (18, e210).

Current guidelines hardly mention the use of topical agents with their various chemical properties (15–18). Their advantage lies in their minimal side effects. In addition, the tactile stimulus when applied by the patients themselves provides better somatotopic representation and motor control. The German guideline points out that dimethyl sulfoxide cream is standard therapy in the Netherlands (15, 26). Other substances with an effect on the central nervous system, such as naltrexone and memantine, as well as immunomodulatory drugs are regarded as experimental and thus not yet recommended (15–18, 26–28, 32, e24, e160, e211, e212).

Physical therapy and medical aids

Passive physical measures, including transcutaneous electrical nerve stimulation (TENS) and acupuncture, are directed primarily at edema and pain relief, and medical aids towards better functionality (Table 2). According to modern guidelines, manual lymphatic drainage is suitable for edema treatment (15, 17), while other procedures are either not mentioned at all or only briefly touched (16–18, 26). There are hardly any studies on this, and these are contradictory. (15–18, 26–28, e24, e213–e217).

Interventional therapies

Where interventional measures reduce—albeit temporarily—pain and restricted movement, they open a window of opportunity for active rehabilitation. Given that they are associated with higher costs, risks and, possibly, repeated experience of pain and helplessness, however, they require a strict indication, especially when they are demanded by the patients themselves (15–18). They are reserved for unequivocal, severe

CRPS where conservative measures have been exhausted (15–18).

According to current guidelines, including the DGN CRPS guideline, there is the option of spinal cord stimulation for intractable CRPS of the lower limbs (eTable 2) (15–18, 26, e218). Recent reviews and a current randomized comparative study suggest that direct dorsal nerve root stimulation has probably fewer side effects and is longer lasting than spinal cord stimulation (15, 18, 34, e219–e224). Intrathecal baclofen may be considered for intractable dystonia (15, 16, 18). So far the evidence is not convincing for any other approaches; for example, with regard to the duration of action of transcranial magnetic stimulation, and the risk-benefit profile of more invasive methods (eTable 2) (15–18, 26–28, e23–e25, 34, e225–e237).

Future prospects

Peripheral and central, physiological and psychological mechanisms appear to work together in CRPS. Diagnosis specificity and treatment effectiveness seem to improve when neuro-psychobehavioral findings are taken into consideration. This is reflected in modern guidelines and the IDC-11, but not yet in the CRPS diagnostic criteria. Sensitive early warning signals, specific clinical criteria and biomarkers, as well as properly targeted prevention/treatment strategies should be further developed—while still maintaining a differentiated look at comorbidities and differential diagnosis.

Conflict of interest statement

Dr. Böhringer received fees from Grüenthal for a presentation.

Prof. Hausteiner-Wiehle received lecture fees and reimbursement of travel expenses from Windach Hospital and the Lindau Psychotherapy Weeks.

Alexandra Melf-Marzi and Dr. Wiehle declare that no conflict of interest exists.

Manuscript received on 21 April 2022, revised version accepted on 17 October 2022.

Translated from the original German by Dr. Grahame Larkin MD

References

1. Harden RN, Bruehl S, Perez RS, et al.: Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. *Pain* 2010; 150: 268–74.
2. Goebel A, Birklein F, Brunner F, et al.: The valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria. *Pain* 2021; 162: 2346–8.
3. World Health Organization: International Classification of Disease 11th Revision. www.icd.who.int/browse11/l-m/en (last accessed on 17 August 2022).
4. Bundesinstitut für Arzneimittel und Medizinprodukte: ICD-11 in Deutsch – Entwurfsfassung. www.bfarm.de/DE/Kodiersysteme/Klassifikationen/ICD/ICD-11/uebersetzung/_node.html (last accessed on 17 August 2022).
5. Maihöfner C, Handwerker HO, Neundörfer B, Birklein F: Cortical reorganization during recovery from complex regional pain syndrome. *Neurology* 2004; 63: 693–701.
6. Grande LA, Loeser JD, Ozuna J, Ashleigh A, Samii A: Complex regional pain syndrome as a stress response. *Pain* 2004; 110: 495–8.
7. Punt DT, Cooper L, Hey M, Johnson MI: Neglect-like symptoms in complex regional pain syndrome: learned nonuse by another name? *Pain* 2013; 154: 200–3.
8. Bruehl S: Complex regional pain syndrome. *BMJ* 2015; 351: h2730.
9. Hausteiner-Wiehle C, Henningsen P: Do we have to rethink complex regional pain syndrome? *J Psychosom Res* 2018; 111: 13–4.
10. Knudsen LF, Terkelsen AJ, Drummond PD, Birklein F: Complex regional pain syndrome: a focus on the autonomic nervous system. *Clin Auton Res* 2019; 29: 457–67.
11. Popkirov S, Hoeritzauer I, Colvin L, Carson AJ, Stone J: Complex regional pain syndrome and functional neurological disorders—time for reconciliation. *J Neurol Neurosurg Psychiatry* 2019; 90: 608–14.
12. Halicka M, Vittersø AD, Proulx MJ, Bultitude JH: Neuropsychological changes in Complex Regional Pain Syndrome (CRPS). *Behav Neurol* 2020; 2020: 4561831.
13. Dimova V, Herrnberger MS, Escolano-Lozano F, et al.: Clinical phenotypes and classification algorithm for complex regional pain syndrome. *Neurology* 2020; 94: e357–67.

14. Goebel A, Andersson D, Helyes Z, Clark JD, Dulake D, Svensson C: The autoimmune aetiology of unexplained chronic pain. *Autoimmun Rev* 2022; 21: 103015.
15. S1-Leitlinie: Diagnostik und Therapie komplexer regionaler Schmerzsyndrome (CRPS), 2018. www.awmf.org/leitlinien/detail/II/030-116.html (last accessed on 15 August 2022).
16. Goebel A, Barker CH, Turner-Stokes L, et al.: Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care. London: RCP, 2018. www.rcplondon.ac.uk/guidelines-policy/complex-regional-pain-syndrome-adults (last accessed on 15 August 2022).
17. Goebel A, Barker C, Birklein F, et al.: Standards for the diagnosis and management of complex regional pain syndrome: results of a European Pain Federation task force. *Eur J Pain* 2019; 23: 641–51.
18. Harden RN, McCabe CS, Goebel A, et al.: Complex regional pain syndrome: practical diagnostic and treatment guidelines, 5th edition. *Pain Med* 2022; 23: 1–53.
19. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC: The incidence of complex regional pain syndrome: a population-based study. *Pain* 2007; 129: 12–20.
20. Sandroni P, Benrud-Larson LM, McClelland RL, Low PA: Complex regional pain syndrome type I: incidence and prevalence in olmsted county, a population-based study. *Pain* 2003; 103: 199–207.
21. de Mos M, Huygen FJ, van der Hoeven-Borgman M, Dieleman JP, Stricker BHC, Sturkenboom MC: Outcome of the complex regional pain syndrome. *Clin J Pain* 2009; 25: 590–7.
22. Speck V, Schlereth T, Birklein F, Maihöfner C: Increased prevalence of posttraumatic stress disorder in CRPS. *Eur J Pain* 2017; 21: 466–73.
23. Tschopp M, Swenenburg J, Wertli MW, et al.: Die deutsche Version der Bath Body Perception Disturbance Scale (BBPDS-D). *Schmerz* 2018; 32: 195–200.
24. Johnson S, Cowell F, Gillespie S, Goebel A: Complex regional pain syndrome what is the outcome?—a systematic review of the course and impact of CRPS at 12 months from symptom onset and beyond. *Eur J Pain* 2022; 26: 1203–20.
25. Terkelsen AJ, Birklein F: Complex regional pain syndrome or limb pain: a plea for a critical approach. *J Pain Res* 2022; 15: 1915–23.
26. Perez RS, Zollinger PE, Dijkstra PU, et al.: CRPS I task force: Evidence based guidelines for complex regional pain syndrome type 1. *BMC Neurol* 2010; 10: 20. Update: www.crps-vereniging.nl/pdf/Executive_summary_guideline_CRPS_I_2014_docx.pdf (last accessed on 22 February 2022).
27. O'Connell NE, Wand BM, McAuley J, Marston L, Moseley GL: Interventions for treating pain and disability in adults with complex regional pain syndrome. *Cochrane Database Syst Rev* 2013; 2013: CD009416.
28. Duong S, Bravo D, Todd KJ, Finlayson RJ, Tran Q: Treatment of complex regional pain syndrome: an updated systematic review and narrative synthesis. *Can J Anaesth* 2018; 65: 658–84.
29. Thieme H, Morkisch N, Rietz C, et al.: The efficacy of movement representation techniques for treatment of limb pain—a systematic review and meta-analysis. *J Pain* 2016; 17: 167–80.
30. Lotze M, Moseley GL: Clinical and neurophysiological effects of progressive movement imagery training for pathological pain. *J Pain* 2022; 23: 1480–91.
31. Smart KM, Ferraro MC, Wand BM, O'Connell NE: Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. *Cochrane Database Syst Rev* 2022; 5: CD010853.
32. Fassio A, Mantovani A, Gatti D, et al.: Rheumatology (Oxford). Pharmacological treatment in adult patients with CRPS-I: a systematic review and meta-analysis of randomised controlled trials. *Rheumatology (Oxford)* 2022; 61: 3534–46.
33. S2k-Leitlinie: Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen. www.awmf.org/leitlinien/detail/II/030-114.html (last accessed on 11 August 2022).
34. Chmiela MA, Hendrickson M, Hale J, et al.: Direct peripheral nerve stimulation for the treatment of complex regional pain syndrome: a 30-year review. *Neuromodulation* 2021; 24: 971–82.

Corresponding author

Prof. Dr. med. Constanze Hausteiner-Wiehle
Department for Neurology, Clinical Neurophysiology and Stroke Unit
BG Trauma Center Murnau, Prof.-Küntschers-Strasse 8, 82418 Murnau
c.hausteiner-wiehle@tum.de

Cite this as:

Melf-Marzi A, Böhringer B, Wiehle M, Hausteiner-Wiehle C: Modern principles of diagnosis and treatment in complex regional pain syndrome. *Dtsch Arztebl Int* 2022; 119: 879–86. DOI: 10.3238/arztebl.m2022.0358

► Supplementary material

eReferences, eTables, eBox:
www.aerzteblatt-international.de/m2022.0358

Supplementary material to:

Modern Principles of Diagnosis and Treatment in Complex Regional Pain Syndrome

by Alexandra Melf-Marzi, Bettina Böhringer, Matthias Wiehle, and Constanze Hausteiner-Wiehle

Dtsch Arztebl Int 2022; 119: 879–86. DOI: 10.3238/arztebl.m2022.0358

eReferences

- e1. Mitchell SW, Morehouse GR, Keen WW: Gunshot wounds and other injuries of nerves. 1864. *Clin Orthop Relat Res* 2007; 35–9.
- e2. Charcot JM: *Clinique des maladies du système nerveux*. Paris: Presse Medicale 1892.
- e3. Sudeck P: Über die akute entzündliche Knochenatrophie. *Arch Klin Chir* 1900; 62: 147–56.
- e4. Oppenheimer H: Die traumatischen Neurosen nach den in der Nervenambulanz der Charité in den letzten 5 Jahren gesammelten Beobachtungen. Berlin: Verlag von August Hirschwald 1889.
- e5. Cassirer R: *Die vasomotorisch-trophischen Neurosen*. Berlin: S. Karger 1901.
- e6. Cramer K: Über metatraumatische vasomotorisch-trophische Neurosen. *Archiv für Orthopädie, Mechanotherapie und Unfallchirurgie* 1909; 7: 341–60.
- e7. Leriche R: *De la causalgie envisagée comme une névrite due sympathique et de son traitement par la dénudation et l'excision des plexus nerveux péri-arteriels*. Paris: Presse Medicale 1916.
- e8. Babinski J: *Hystérie-pithiatisme et troubles nerveux d'ordre réflexe en neurologie de guerre*. Paris: Masson et Cie 1917.
- e9. Evans JA: Reflex sympathetic dystrophy. *Surg Clin North Am* 1946; 26: 780–90.
- e10. Merskey H, Bogduk N: *International Association for the Study of Pain. Task Force on Taxonomy: classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms*. 2nd edition. Seattle (WA): IASP Press 1994.
- e11. Nicholas M, Vlaeyen JWS, Rief W, et al.: IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic primary pain. *Pain* 2019; 160: 28–37.
- e12. Treede RD, Hoheisel U, Wang D, Magerl W: Central sensitization: clinical utility of a physiological concept for the International Statistical Classification of Diseases and Related Health Problems and for nociplastic pain. *Pain* 2022; 163 (Suppl 1): 99–107.
- e13. Popkirov S, Enax-Krumova EK, Mainka T, Hoheisel M, Hausteiner-Wiehle C: Functional pain disorders—more than nociplastic pain. *NeuroRehabilitation* 2020; 47: 343–53.
- e14. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W: Nociplastic pain: towards an understanding of prevalent pain conditions. *Lancet* 2021; 397(10289): 2098–110.
- e15. Moseley GL: Reconceptualising pain according to its underlying biology. *Phys Ther Rev* 2007; 12: 169–78.
- e16. Wiech K: Deconstructing the sensation of pain: the influence of cognitive processes on pain perception. *Science* 2016; 354 (6312): 584–7.
- e17. Di Lernia D, Serino S, Riva G: Pain in the body. Altered interoception in chronic pain conditions: a systematic review. *Neurosci Biobehav Rev* 2016; 71: 328–41.
- e18. Henningsen P, Gündel H, Kop WJ, et al.: EURONET-SOMA Group: persistent physical symptoms as perceptual dysregulation: a neuropsychobehavioral model and its clinical implications. *Psychosom Med* 2018; 80: 422–31.
- e19. Greenwald JD, Shafritz KM: An integrative neuroscience framework for the treatment of chronic pain: from cellular alterations to behavior. *Front Integr Neurosci* 2018; 12: 18.
- e20. Kuner R, Kuner T: Cellular circuits in the brain and their modulation in acute and chronic pain. *Physiol Rev* 2021; 101: 213–58.
- e21. Bircklein F, Schlereth T: Complex regional pain syndrome—significant progress in understanding. *Pain* 2015; 156: 94–103.
- e22. Bircklein F, Ajit SK, Goebel A, Perez RSGM, Sommer C: Complex regional pain syndrome—phenotypic characteristics and potential biomarkers. *Nat Rev Neurol* 2018; 14: 272–84.
- e23. Shim H, Rose J, Halle S, Shekane P: Complex regional pain syndrome: a narrative review for the practising clinician. *Br J Anaesth* 2019; 123: e424–e33.
- e24. Taylor SS, Noor N, Urits I, et al.: Complex regional pain syndrome: a comprehensive review. *Pain Ther* 2021; 10: 875–92.
- e25. Rebhorn C, Dimova V, Bircklein F: Komplexes regionales Schmerzsyndrom—ein Update. *Nervenarzt* 2021; 92: 1075–83.
- e26. Ott S, Maihöfner C: Signs and symptoms in 1,043 patients with complex regional pain syndrome. *J Pain* 2018; 19: 599–611.
- e27. Bircklein F, Riedl B, Sieweke N, Weber M, Neundörfer B: Neurological findings in complex regional pain syndromes—analysis of 145 cases. *Acta Neurol Scand* 2000; 101: 262–9.
- e28. Beerthuizen A, Stronks DL, Van't Spijker A, et al.: Demographic and medical parameters in the development of complex regional pain syndrome type 1 (CRPS1): prospective study on 596 patients with a fracture. *Pain* 2012; 153: 1187–92.
- e29. Baerg K, Tupper SM, Chu LM, et al.: Canadian surveillance study of complex regional pain syndrome in children. *Pain* 2022; 163: 1060–9.
- e30. Abu-Arafah H, Abu-Arafah I: Complex regional pain syndrome in children: incidence and clinical characteristics. *Arch Dis Child* 2016; 101: 719–23.
- e31. Duenes M, Schoof L, Schwarzkopf R, Meftah M: Complex regional pain syndrome following total knee arthroplasty. *Orthopedics* 2020; 43: e486–e491.
- e32. Magone KM, Ben-Ari E, Hacquebord JH, Virk MS: Complex regional pain syndrome following shoulder surgery. *Arthrosc Sports Med Rehabil* 2021; 3: e1037–45.
- e33. Bruehl S, Billings FT 4th, Anderson S, et al.: Preoperative predictors of complex regional pain syndrome outcomes in the 6 months following total knee arthroplasty. *J Pain* 2022; 23: 1712–23.
- e34. Sousa LHA, O Costa C, Novak EM, Giostri GS: Complex regional pain syndrome after carpal tunnel syndrome surgery: a systematic review. *Neurol India* 2022; 70: 491–503.
- e35. Roh YH, Lee BK, Noh JH, et al.: Factors associated with complex regional pain syndrome type I in patients with surgically treated distal radius fracture. *Arch Orthop Trauma Surg* 2014; 134: 1775–81.
- e36. Sumitani M, Yasunaga H, Uchida K, et al.: Perioperative factors affecting the occurrence of acute complex regional pain syndrome following limb bone fracture surgery: data from the Japanese Diagnosis Procedure Combination database. *Rheumatology (Oxford)* 2014; 53: 1186–93.
- e37. Ortiz-Romero J, Bermudez-Soto I, Torres-González R, Espinoza-Choque F, Zazueta-Hernandez JA, Perez-Atanasio JM: Factors associated with complex regional pain syndrome in surgically treated distal radius fracture. *Acta Ortop Bras* 2017; 25: 194–6.
- e38. Savaş S, İnal EE, Yavuz DD, Uslusoy F, Altuntaş SH, Aydın MA: Risk factors for complex regional pain syndrome in patients with surgically treated traumatic injuries attending hand therapy. *J Hand Ther* 2017; pii: 0894–1130.
- e39. Moseley GL, Herbert RD, Parsons T, Lucas S, Van Hilten JJ, Marinus J: Intense pain soon after wrist fracture strongly predicts who will develop complex regional pain syndrome: prospective cohort study. *J Pain* 2014; 15: 16–23.
- e40. Wertli M, Bachmann LM, Weiner SS, Brunner F: Prognostic factors in complex regional pain syndrome 1: a systematic review. *J Rehabil Med* 2013; 45: 225–31.
- e41. Su YC, Guo YH, Hsieh PC, Lin YC: A meta-analysis and meta-regression of frequency and risk factors for poststroke complex regional pain syndrome. *Medicina (Kaunas)* 2021; 57: 1232.
- e42. Farzad M, Layeghi F, Hosseini A, et al.: Investigate the effect of psychological factors in development of complex regional pain syndrome type I in patients with fracture of the distal radius: a prospective study. *J Hand Surg Asian Pac Vol* 2018; 23: 554–61.

- e43. Berry JD, Rowbotham MC, Petersen KL: Complex regional pain syndrome-like symptoms during herpes zoster. *Pain* 2004; 110: 8–9.
- e44. Richards S, Chalkiadis G, Lakshman R, Buttery JP, Crawford NW: Complex regional pain syndrome following immunisation. *Arch Dis Child* 2012; 97: 913–5.
- e45. Goenka A, Aziz M, Riley P, Vassallo G: Complex regional pain syndrome involving the face following snowball injury. *Eur J Pediatr* 2014; 173: 397–400.
- e46. Oh SW, Choi SU, Park M, Shin JH: Validity of the Budapest criteria for poststroke complex regional pain syndrome. *Clin J Pain* 2019; 35: 831–5.
- e47. Chae J: Poststroke complex regional pain syndrome. *Top Stroke Rehabil* 2010; 17: 151–62.
- e48. Kocabas H, Levendoglu F, Ozerbil OM, Yuruten B: Complex regional pain syndrome in stroke patients. *Int J Rehabil Res* 2007; 30: 33–8.
- e49. Pertoldi S, Di Benedetto P: Shoulder-hand syndrome after stroke. A complex regional pain syndrome. *Eura Medicophys* 2005; 41: 283–92.
- e50. Jang SH, Seo YS: Diagnosis of complex regional pain syndrome I following traumatic axonal injury of the corticospinal tract in a patient with mild traumatic brain injury. *Diagnostics (Basel)* 2020; 10: 95.
- e51. Chung HS, Kim SM, Chang MC, et al.: Diagnosis of complex regional pain syndrome type 1 in patients with corticobasal degeneration: a case report. *Ann Palliat Med* 2021; 10: 5825–30.
- e52. Gofitã CE, Ciurea ME, Dinescu ȘC, et al.: Complex regional pain syndrome as a paraneoplastic disorder associated with metastypical basal cell carcinoma. *Rom J Morphol Embryol* 2019; 60: 685–9.
- e53. de Rooij AM, Perez RS, Huygen FJ, et al.: Spontaneous onset of complex regional pain syndrome. *Eur J Pain* 2010; 14: 510–3.
- e54. Lipman MD, Hess DE, Werner BC, Deal DN: Fibromyalgia as a predictor of complex regional pain syndrome after distal radius fracture. 2019; 14: 516–22.
- e55. Crijns TJ, van der Gronde BATD, Ring D, Leung N: Complex regional pain syndrome after distal radius fracture is uncommon and is often associated with fibromyalgia. *Clin Orthop Relat Res* 2018; 476: 744–50.
- e56. Peterlin BL, Rosso AL, Nair S, Young WB, Schwartzman RJ: Migraine may be a risk factor for the development of complex regional pain syndrome. *Cephalalgia* 2010; 30: 214–23.
- e57. de Mos M, Huygen FJ, Dieleman JP, Koopman JS, Stricker BH, Sturkenboom MC: Medical history and the onset of complex regional pain syndrome (CRPS). *Pain* 2009; 139: 458–66.
- e58. Beerthuizen A, van't Spijker A, Huygen FJ, Klein J, de Wit R: Is there an association between psychological factors and the complex regional pain syndrome type 1 (CRPS1) in adults? A systematic review. *Pain* 2009; 145: 52–9.
- e59. Hüge V, Lauchart M, Magerl W, et al.: Complex interaction of sensory and motor signs and symptoms in chronic CRPS. *PLoS One* 2011; 6: e18775.
- e60. Dilek B, Yemez B, Kizil R, et al.: Anxious personality is a risk factor for developing complex regional pain syndrome type I. *Rheumatol Int* 2012; 32: 915–20.
- e61. Bean DJ, Johnson MH, Heiss-Dunlop W, Lee AC, Kydd RR: Do psychological factors influence recovery from complex regional pain syndrome type 1? A prospective study. *Pain* 2015; 156: 2310–8.
- e62. Farzad M, MacDermid JC, Packham T, Khodabandeh B, Vahedi M, Shafiee E: Factors associated with disability and pain intensity in patients with complex regional pain syndrome. *Disabil Rehabil* 2021; 1–9.
- e63. Antunovich DR, Horne JC, Tuck NL, Bean DJ: Are illness perceptions associated with pain and disability in complex regional pain syndrome? A cross-sectional study. *Pain Med* 2021; 22: 100–11.
- e64. Beerthuizen A, Stronks DL, Huygen FJ, Passchier J, Klein J, Spijker AV: The association between psychological factors and the development of complex regional pain syndrome type 1 (CRPS1)—a prospective multicenter study. *Eur J Pain* 2011; 15: 971–5.
- e65. Lohnberg JA, Altmaier EM: A review of psychosocial factors in complex regional pain syndrome. *J Clin Psychol Med Settings* 2013; 20: 247–54.
- e66. Park HY, Jang YE, Oh S, Lee PB: Psychological characteristics in patients with chronic complex regional pain syndrome: comparisons with patients with major depressive disorder and other types of chronic pain. *J Pain Res* 2020; 13: 389–98.
- e67. Melis M, Zawawi K, al-Badawi E, Lobo Lobo S, Mehta N: Complex regional pain syndrome in the head and neck: a review of the literature. *J Orofac Pain* 2002; 16: 93–104.
- e68. Parkitny L, Wand BM, Graham C, Quintner J, Moseley G: Interdisciplinary management of complex regional pain syndrome of the face. *Phys Ther* 2016; 96: 1067–73.
- e69. Jokonya L, Mungazi S, Mduluzi-Jokonya TL, Kalangu KKN: Truncal complex regional pain syndrome, myth or reality: case report. *Int J Surg Case Rep* 2021; 83: 105959.
- e70. Galer BS, Jensen M: Neglect-like symptoms in complex regional pain syndrome: results of a self-administered survey. *J Pain Symptom Manage* 1999; 18: 213–7.
- e71. Moseley L: Distorted body image in complex regional pain syndrome. *Neurology* 2005; 65: 773.
- e72. Frettlöh J, Hüppe M, Maier C: Severity and specificity of neglect-like symptoms in patients with complex regional pain syndrome (CRPS) compared to chronic limb pain of other origins. *Pain* 2006; 124: 184–9.
- e73. Lewis JS, Kersten P, McCabe CS, McPherson KM, Blake DR: Body perception disturbance: a contribution to pain in complex regional pain syndrome (CRPS). *Pain* 2007; 133: 111–9.
- e74. Bean DJ, Johnson MH, Heiss-Dunlop W, Kydd RR: Extent of recovery in the first 12 months of complex regional pain syndrome type-1: a prospective study. *Eur J Pain* 2016; 20: 884–94.
- e75. Kolb L, Lang C, Seifert F, Maihöfner C: Cognitive correlates of „neglect-like syndrome“ in patients with complex regional pain syndrome. *Pain* 2012; 153: 1063–73.
- e76. Ten Brink AF, Bultitude JH: Predictors of self-reported neglect-like symptoms and involuntary movements in complex regional pain syndrome compared to other chronic limb pain conditions. *Pain Med* 2021; 22: 2337–49.
- e77. Ten Brink AF, Halicka M, Vittersø AD, Jones HG, Stanton TR, Bultitude JH: Validation of the Bath CRPS Body Perception Disturbance Scale. *J Pain* 2021; 22: 1371–84.
- e78. Lewis JS, Kersten P, McPherson KM, et al.: Wherever is my arm? Impaired upper limb position accuracy in complex regional pain syndrome. *Pain* 2010; 149: 463–9.
- e79. Reinersmann A, Landwehrt J, Krumova EK, Ocklenburg S, Güntürkün O, Maier C: Impaired spatial body representation in complex regional pain syndrome type 1 (CRPS I). *Pain* 2012; 153: 2174–81.
- e80. Lewis JS, McCabe C: Body perception disturbance (BPD) in CRPS. *Pract Pain Manag* 2010; 10: 60–6.
- e81. Wittayer M, Dimova V, Birklein F, Schlereth T: Correlates and importance of neglect-like symptoms in complex regional pain syndrome. *Pain* 2018; 159: 978–86.
- e82. Michal M, Adler J, Reiner I, et al.: Association of neglect-like symptoms with anxiety, somatization, and depersonalization in complex regional pain syndrome. *Pain Med* 2017; 18: 764–72.
- e83. Margalit D, Ben Har L, Brill S, Vatine JJ: Complex regional pain syndrome, alexithymia, and psychological distress. *J Psychosom Res* 2014; 77: 273–7.
- e84. Kuttikat A, Shaikh M, Oomatia A, Parker R, Shenker N: Novel signs and their clinical utility in diagnosing complex regional pain syndrome (CRPS): a prospective observational cohort study. *Clin J Pain* 2017; 33: 496–502.
- e85. Förderreuther S, Sailer U, and Straube A: Impaired self-perception of the hand in complex regional pain syndrome (CRPS). *Pain* 2004; 110: 756–61.
- e86. Reinersmann A, Haarmeyer GS, Blankenburg M, et al.: Left is where the L is right. Significantly delayed reaction time in limb laterality recognition in both CRPS and phantom limb pain patients. *Neurosci Lett* 2010; 486: 240–5.
- e87. Peltz E, Seifert F, Lanz S, Müller R, Maihöfner C: Impaired hand size estimation in CRPS. *J Pain* 2011; 12: 1095–101.
- e88. Moseley GL, Zalucki N, Birklein F, Marinus J, van Hilten JJ, Luomajoki H: Thinking about movement hurts: the effect of motor imagery on pain and swelling in people with chronic arm pain. *Arthritis Rheum* 2008; 59: 623–31.
- e89. Echalié A, Borg C, Creac'h C, Laurent B, Michael GA: Spontaneous sensations reveal distorted body perception in complex regional pain syndrome (CRPS). *Brain Cogn* 2020; 142: 105568.
- e90. Vittersø AD, Buckingham G, Halicka M, Proulx MJ, Bultitude JH: Altered updating of bodily and spatial representations after tool-use in complex regional pain syndrome. *Pain* 2020; 161: 1609–28.
- e91. Brown CA, Scholtes I, Shenker N, Lee MC: Suboptimal learning of tactile-spatial predictions in patients with complex regional pain syndrome. *Pain* 2020; 161: 369–78.

- e92. Kim J, Kang I, Chung YA, et al.: Altered attentional control over the salience network in complex regional pain syndrome. *Sci Rep* 2018; 8: 7466.
- e93. Christophe L, Delporte L, Revol P, et al.: Complex regional pain syndrome associated with hyperattention rather than neglect for the healthy side: a comprehensive case study. *Ann Phys Rehabil Med* 2016; 59: 294–301.
- e94. Halicka M, Vittersø AD, Proulx MJ, Bultitude JH: Attention upturned: bias toward and away from the affected side of the body and near space in a case of complex regional pain syndrome. *Neuropsychologia* 2021; 163: 108079.
- e95. Mainka T, Bischoff FS, Baron R, et al.: Comparison of muscle and joint pressure-pain thresholds in patients with complex regional pain syndrome and upper limb pain of other origin. *Pain* 2014; 155: 591–7.
- e96. Moseley GL, Gallace A, Di Pietro F, Spence C, Iannetti GD: Limb-specific autonomic dysfunction in complex regional pain syndrome modulated by wearing prism glasses. *Pain* 2013; 154: 2463–8.
- e97. Bartur G, Vatine JJ, Raphaely-Beer N, Peleg S, Katz-Leurer M: Heart rate autonomic regulation system at rest and during paced breathing among patients with CRPS as compared to age-matched healthy controls. *Pain Med* 2014; 15: 1569–74.
- e98. Cohen HE, Hall J, Harris N, McCabe CS, Blake DR, Janig W: Enhanced pain and autonomic responses to ambiguous visual stimuli in chronic complex regional pain syndrome (CRPS) type I. *Eur J Pain* 2012; 16: 182–95.
- e99. Terkelsen AJ, Mølgaard H, Hansen J, Finnerup NB, Krøner K, Jensen TS: Heart rate variability in complex regional pain syndrome during rest and mental and orthostatic stress. *Anesthesiology* 2012; 116: 133–46.
- e100. Schürmann M, Gragl G, Zaspel J, Kayser M, Löhner P, Andress HJ: Peripheral sympathetic function as a predictor of complex regional pain syndrome type I (CRPS I) in patients with radial fracture. *Auton Neurosci* 2000; 86: 127–34.
- e101. Alam OH, Zaidi B, Pierce J, et al.: Phenotypic features of patients with complex regional pain syndrome compared with those with neuropathic pain. *Reg Anesth Pain Med* 2019: rapm-2019-100511.
- e102. Dietz C, Reinhold AK, Escolano-Lozano F, et al.: Complex regional pain syndrome: role of contralateral sensitisation. *Br J Anaesth* 2021; 127: e1–e3.
- e103. Enax-Krumova EK, Baron R, Treede RD, Vollert J: Contralateral sensitisation is not specific for complex regional pain syndrome. *Comment on Br J Anaesth* 2021; 127: e1–3. *Br J Anaesth* 2021; 127: e173–e6.
- e104. Marinus J, Van Hilten JJ: Clinical expression profiles of complex regional pain syndrome, fibromyalgia and a-specific repetitive strain injury: more common denominators than pain? *Disabil Rehabil* 2006; 28: 351–62.
- e105. van Rooijen DE, Marinus J, van Hilten JJ: Muscle hyperalgesia is widespread in patients with complex regional pain syndrome. *Pain* 2013; 154: 2745–9.
- e106. Birley T, Goebel A: Widespread pain in patients with complex regional pain syndrome. *Pain Pract* 2014; 14: 526–31.
- e107. Martínez-Lavín M, Vargas A, Silveira LH, Amezcua-Guerra LM, Martínez-Martínez LA, Pineda C: Complex regional pain syndrome evolving to full-blown fibromyalgia: a proposal of common mechanisms. *J Clin Rheumatol* 2021; 27: 274–7.
- e108. Bean DJ, Johnson MH, Kydd RR: Relationships between psychological factors, pain, and disability in complex regional pain syndrome and low back pain. *Clin J Pain* 2014; 30: 647–53.
- e109. Munts AG, Van Rootselaar AF, Van Der Meer JN, Koelman JH, Van Hilten JJ, Tijssen MA: Clinical and neurophysiological characterization of myoclonus in complex regional pain syndrome. *Mov Disord* 2008; 23: 581–7.
- e110. Lang AE, Angel M, Bhatia K, et al.: Myoclonus in complex regional pain syndrome. *Mov Disord* 2009; 24: 314–6; author reply 316.
- e111. Schrag A, Trimble M, Quinn N, Bhatia K: The syndrome of fixed dystonia: an evaluation of 103 patients. *Brain* 2004; 127: 2360–72.
- e112. Singh D: Functional dystonia: a pitfall for the foot and ankle surgeon. *Foot Ankle Surg* 2022; 28: 691–6.
- e113. Gray J, Welck M, Cullen NP, Singh D: Functional dystonia in the foot and ankle. *Bone Joint J* 2021; 103-B: 1127–32.
- e114. Simmons BP, Vasile RG: The clenched fist syndrome. *J Hand Surg Am* 1980; 5: 420–7.
- e115. Gragl G, Steinborn M, Witzgall I, Mittlmeier T, Schürmann M: Das akute CRPS I (Morbus Sudeck) nach distaler Radiusfraktur—Methoden der Frühdiagnostik. *Zentrabl Chir* 2003; 128: 1020–6.
- e116. Agten CA, Kobe A, Barnaure I, Galley J, Pfirrmann CW, Brunner F: MRI of complex regional pain syndrome in the foot. *Eur J Radiol* 2020; 129: 109044.
- e117. Graif M, Schweitzer ME, Marks B, Matteucci T, Mandel S: Synovial effusion in reflex sympathetic dystrophy: an additional sign for diagnosis and staging. *Skeletal Radiol* 1998; 27: 262–5.
- e118. Schürmann M, Zaspel J, Löhner P, et al.: Imaging in early posttraumatic complex regional pain syndrome: a comparison of diagnostic methods. *Clin J Pain* 2007; 23: 449–57.
- e119. Wüppenhorst N, Maier C, Frettlöh J, Pennekamp W, Nicolas V: Sensitivity and specificity of 3-phase bone scintigraphy in the diagnosis of complex regional pain syndrome of the upper extremity. *Clin J Pain* 2010; 26: 182–9.
- e120. Cheon M, Kang HJ, Do KH, Yang HS, Han EJ, Yoo J: Diagnostic performance of three-phase bone scintigraphy and digital infrared thermography imaging for chronic post-traumatic complex regional pain syndrome. *Diagnostics (Basel)* 2021; 11: 1459.
- e121. Wertli MM, Brunner F, Steurer J, Held U: Usefulness of bone scintigraphy for the diagnosis of complex regional pain syndrome 1: a systematic review and Bayesian meta-analysis. *PLoS One* 2017; 12: e0173688.
- e122. Wasner G, Schattschneider J, Baron R: Skin temperature side differences—a diagnostic tool for CRPS? *Pain* 2002; 98: 19–26.
- e123. Krumova EK, Frettlöh J, Klauenberg S, Richter H, Wasner G, Maier C: Long-term skin temperature measurements—a practical diagnostic tool in complex regional pain syndrome. *Pain* 2008; 140: 8–22.
- e124. Packham T, MacDermid J, Bain J, Buckley N: Identification of complex regional pain syndrome in the upper limb: skin temperature asymmetry after cold pressor test. *Can J Pain* 2018; 2: 248–57.
- e125. Dietz C, Müller M, Reinhold AK, et al.: What is normal trauma healing and what is complex regional pain syndrome? An analysis of clinical and experimental biomarkers. *Pain* 2019; 160: 2278–89.
- e126. Krämer HH, Hofbauer LC, Szalay G, et al.: Osteoprotegerin: a new biomarker for impaired bone metabolism in complex regional pain syndrome? *Pain* 2014; 155: 889–95.
- e127. Bruehl S, Harden RN, Galer BS, Saltz S, Backonja M, Stanton-Hicks M: Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome? *Pain* 2002; 95: 119–24.
- e128. Bruehl S, Maihöfner C, Stanton-Hicks M, et al.: Complex regional pain syndrome: evidence for warm and cold subtypes in a large prospective clinical sample. *Pain* 2016; 157: 1674–81.
- e129. Vaneker M, Wilder-Smith OH, Schrombges P, de Man-Hermens I, Oerlemans HM: Patients initially diagnosed as „warm“ or „cold“ CRPS 1 show differences in central sensory processing some eight years after diagnosis: a quantitative sensory testing study. *Pain* 2005; 115: 204–11.
- e130. Bean DJ, Johnson MH, Kydd RR: The outcome of complex regional pain syndrome type 1: a systematic review. *J Pain* 2014; 15: 677–90.
- e131. Brunner F, Bachmann LM, Perez RSGM, Marinus J, Wertli MM: Painful swelling after a noxious event and the development of complex regional pain syndrome 1: a one-year prospective study. *Eur J Pain* 2017; 21: 1611–7.
- e132. Llewellyn A, McCabe CS, Hibberd Y, et al.: Are you better? A multi-centre study of patient-defined recovery from complex regional pain syndrome. *Eur J Pain* 2018; 22: 551–64.
- e133. van Rijn MA, Marinus J, Putter H, Bosselaar SR, Moseley GL, van Hilten JJ: Spreading of complex regional pain syndrome: not a random process. *J Neural Transm (Vienna)* 2011; 118: 1301–9.
- e134. Maleki J, LeBel AA, Bennett GJ, Schwartzman RJ: Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy). *Pain* 2000; 88: 259–66.
- e135. Enax-Krumova E, Tegenthoff M: Diagnosesicherung bei der Begutachtung des komplexen regionalen Schmerzsyndroms (CRPS). *Med Sach* 2017; 113: 222–5.
- e136. Lunden LK, Jorum E: The challenge of recognizing severe pain and autonomic abnormalities for early diagnosis of CRPS. *Scand J Pain* 2021; 21: 548–59.
- e137. Mailis-Gagnon A, Lakha SF, Allen MD, Deshpande A, Harden RN: Characteristics of complex regional pain syndrome in patients referred to a tertiary pain clinic by community physicians, assessed by the Budapest clinical diagnostic criteria. *Pain Med* 2014; 15: 1965–74.
- e138. Del Piñal F: Editorial. I have a dream ... reflex sympathetic dystrophy (RSD or Complex Regional Pain Syndrome—CRPS I) does not exist. *J Hand Surg Eur Vol* 2013; 38: 595–7.

- e139. Borchers AT, Gershwin ME: The clinical relevance of complex regional pain syndrome type I: the emperor's new clothes. *Autoimmun Rev* 2017; 16: 22–33.
- e140. Mailis-Gagnon A, Nicholson K, Blumberg D, Zurowski M: Characteristics and period prevalence of self-induced disorder in patients referred to a pain clinic with the diagnosis of complex regional pain syndrome. *Clin J Pain* 2008; 24: 176–85.
- e141. Secrétan H: Oedème dure et hyperplasie traumatique du métacarpe dorsal. *Rev Med Suisse Rom* 1901; 21: 409.
- e142. Reading G: Secretan's syndrome: hard edema of the dorsum of the hand. *Plast Reconstruct Surg* 1980; 65: 182–7.
- e143. Bass C, Yates G: Complex regional pain syndrome type 1 in the medico-legal setting: high rates of somatoform disorders, opiate use and diagnostic uncertainty. *Med Sci Law* 2018; 58: 147–55.
- e144. Wehking E: Das komplexe regionale Schmerzsyndrom (CRPS) in Abgrenzung psychogener Störungen. *Versicherungsmedizin* 2007; 59: 16–9.
- e145. Ochoa JL, Verdugo RJ: Neuropathic pain syndrome displayed by malingers. *J Neuropsychiatry Clin Neurosci* 2010; 22: 278–86.
- e146. 2k-Leitlinie Ärztliche Begutachtung von Menschen mit chronischen Schmerzen (Leitlinie Schmerzbegutachtung). <https://www.awmf.org/leitlinien/detail/ll/094-003.html> (last accessed on 17 August 2022).
- e147. Simmel S, Papenhoff MC, Reimertz C, AG Rehabilitation der BG Kliniken, AG Schmerzmedizin der BG Kliniken: Stufenmodell der Schmerzrehabilitation in den BG Kliniken. *Trauma Berufskrankh* 2019; 21: 193–8.
- e148. S3-Leitlinie Behandlung akuter perioperativer und posttraumatischer Schmerzen. <https://www.awmf.org/leitlinien/detail/anmeldung/1/ll/001-025.html> (last accessed on 10 August 2022).
- e149. Akoglu G, Emre S, Metin A, Bozkurt M: High frequency of hypertrichosis after cast application. *Dermatology* 2012; 225: 70–4.
- e150. Terkelsen AJ, Bach FW, Jensen TS: Experimental forearm immobilization in humans induces cold and mechanical hyperalgesia. *Anesthesiology* 2008; 109: 297–307.
- e151. Singh HP, Davis TR: The effect of short-term dependency and immobility on skin temperature and colour in the hand. *J Hand Surg Br* 2006; 31: 611–5.
- e152. Gillespie S, Cowell F, Cheung GC, Brown DJ: Can we reduce the incidence of complex regional pain syndrome type I in distal radius fractures? The Liverpool experience. *Hand Ther* 2016; 21: 123–30.
- e153. Boersma EZ, Meent HV, Klomp FP, Frölke JM, Nijhuis-van der Sanden MWG, Edwards MJR: Treatment of distal radius fracture: does early activity postinjury lead to a lower incidence of complex regional pain syndrome? *Hand (N Y)* 2022; 17: 119–27.
- e154. Dilek B, Ayhan C, Yagci G, Yakut Y: Effectiveness of the graded motor imagery to improve hand function in patients with distal radius fracture: a randomized controlled trial. *J Hand Ther* 2018; 31: 2–9.
- e155. Hung KC, Chiang MH, Wu SC, et al.: A meta-analysis of randomized clinical trials on the impact of oral vitamin C supplementation on first-year outcomes in orthopedic patients. *Sci Rep* 2021; 11: 9225.
- e156. Seth I, Bulloch G, Seth N, et al: Effect of perioperative vitamin C on the incidence of complex regional pain syndrome: a systematic review and meta-analysis. *J Foot Ankle Surg* 2022; 61: 748–54.
- e157. McCormick ZL, Gagnon CM, Caldwell M, et al.: Short-term functional, emotional, and pain outcomes of patients with complex regional pain syndrome treated in a comprehensive interdisciplinary pain management program. *Pain Med* 2015; 16: 2357–67.
- e158. Lewis JS, Kellett S, McCullough R, et al.: Body perception disturbance and pain reduction in longstanding complex regional pain syndrome following a multidisciplinary rehabilitation program. *Pain Med* 2019; 20: 2213–9.
- e159. Bruehl S, Chung OY: Psychological and behavioral aspects of complex regional pain syndrome management. *Clin J Pain* 2006; 22: 430–7.
- e160. Elomaa M, Hotta J, de C Williams AC, et al.: Symptom reduction and improved function in chronic CRPS type 1 after 12-week integrated, interdisciplinary therapy. *Scand J Pain* 2019; 19: 257–70.
- e161. Kotsougiani-Fischer D, Choi JS, Oh-Fischer JS, et al.: ICF-based multidisciplinary rehabilitation program for complex regional pain syndrome of the hand: efficacy, long-term outcomes, and impact of therapy duration. *BMC Surg* 2020; 20: 306.
- e162. Raqué J, Chung BY, Benrath J: Wirksamkeit einer interdisziplinären multimodalen stationären Schmerztherapie (IMST) bei Patienten mit komplexem regionalem Schmerzsyndrom (CRPS). Eine retrospektive Studie. *Schmerz* 2022; 36: 81–8.
- e163. Oerlemans HM, Oostendorp RA, de Boo T, Goris RJ: Pain and reduced mobility in complex regional pain syndrome I: outcome of a prospective randomised controlled clinical trial of adjuvant physical therapy versus occupational therapy. *Pain* 1999; 83: 77–83.
- e164. Oerlemans H, Goris J, de Boo T, Oostendorp R: Do physical therapy and occupational therapy reduce the impairment percentage in reflex sympathetic dystrophy? *Am J Phys Med Rehabil* 1999; 78: 533–9.
- e165. McCabe C, Haigh R, Ring E, Halligan P, Wall P, Blake D: A controlled pilot study of the utility of mirror visual feedback in the treatment of complex regional pain syndrome (type 1). *Rheumatology (Oxford)* 2002; 42: 97–101.
- e166. Moseley GL: Graded motor imagery is effective for longstanding complex regional pain syndrome: a randomised controlled trial. *Pain* 2004; 108: 192–8.
- e167. Moseley GL: Graded motor imagery for pathologic pain: a randomized controlled trial. *Neurology* 2006; 67: 2129–34.
- e168. Cacchio A, De Blasis E, Necozione S, di Orio F, Santilli V: Mirror therapy for chronic complex regional pain syndrome type 1 and stroke. *N Engl J Med* 2009; 361: 634–6.
- e169. Johnson S, Hall J, Barnett S, et al.: Using graded motor imagery for complex regional pain syndrome in clinical practice: failure to improve pain. *Eur J Pain* 2012; 16: 550–61.
- e170. McCabe C: Mirror visual feedback therapy. A practical approach. *J Hand Ther* 2011; 24: 170–8.
- e171. Storz C, Kraft E: Ergotherapie bei Komplexem regionalem Schmerzsyndrom. *Schmerz* 2021; 35: 285–93.
- e172. Cuenca-Martinez F, Reina-Varona Á, Castillo-García J, et al.: Pain relief by movement representation strategies: an umbrella and mapping review with meta-analysis of motor imagery, action observation and mirror therapy. *Eur J Pain* 2022; 26: 284–309.
- e173. O'Neil O, Fernandez MM, Herzog J, et al.: Virtual reality for neurorehabilitation: insights from 3 European clinics. *PM R* 2018; 10: S198–206.
- e174. Kraft E, Azad SC: Exergames—eine neue Therapieoption bei CRPS? *Schmerz* 2020; 34: 113–4.
- e175. Noigroup: Recognize app. www.noigroup.com/product/recogniseapp/ (last accessed on 20 August 2022).
- e176. Reflex Pain Management. www.reflexpainmanagement.com/index.php?main_page=document_general_info&cPath=81&products_id=220 (last accessed on 20 August 2022).
- e177. Graded Motor Imagery. www.gradedmotorimagery.com/index.html (last accessed on 20 August 2022).
- e178. Turton AJ, Palmer M, Grieve S, et al.: Evaluation of a prototype tool for communicating body perception disturbances in complex regional pain syndrome. *Front Hum Neurosci* 2013; 7: 517–23.
- e179. Wiederhold BK, Gao K, Sulea C, Wiederhold MD: Virtual reality as a distraction technique in chronic pain patients. *Cyberpsychol Behav Soc Netw* 2014; 17: 346–52.
- e180. Triberti S, Repetto C, Riva G: Psychological factors influencing the effectiveness of virtual reality–based analgesia: a systematic review. *Cyberpsychol Behav Soc Netw* 2014; 17: 335–45.
- e181. Hwang H, Cho S, Lee JH: The effect of virtual body swapping with mental rehearsal on pain intensity and body perception disturbance in complex regional pain syndrome. *Int J Rehabil Res* 2014; 37: 167–72.
- e182. de Jong JR, Vlaeyen JW, Onghena P, Cuyppers C, den Hollander M, Ruijgrok J: Reduction of pain-related fear in complex regional pain syndrome type I: the application of graded exposure in vivo. *Pain* 2005; 116: 264–75.
- e183. Ek JW, van Gijn JC, Samwel H, van Egmond J, Klomp FP, van Dongen RT: Pain exposure physical therapy may be a safe and effective treatment for longstanding complex regional pain syndrome type 1: a case series. *Clin Rehabil* 2009; 23: 1059–66.
- e184. Barnhoom KJ, van de Meent H, van Dongen RT, et al.: Pain exposure physical therapy (PEPT) compared to conventional treatment in complex regional pain syndrome type 1: a randomised controlled trial. *BMJ Open* 2015; 5: e008283.
- e185. den Hollander M, Goossens M, de Jong J, et al.: Expose or protect? A randomized controlled trial of exposure in vivo vs pain-contingent treatment as usual in patients with complex regional pain syndrome type 1. *Pain* 2016; 157: 2318–29.
- e186. Thomson L: Hypnotherapy for complex regional pain syndrome. *Am J Clin Hypn* 2022; 64: 195–205.
- e187. Lebon J, Rongièrès M, Apredoaeci C, Delclaux S, Mansat P: Physical therapy under hypnosis for the treatment of patients with type 1 complex regional pain syndrome of the hand and wrist: retrospective study of 20 cases. *Hand Surg Rehabil* 2017; 36: 215–21.

- e188. McKittrick ML, Connors EL, McKernan LC: Hypnosis for chronic neuropathic pain: a scoping review. *Pain Med* 2022; 23: 1015–26.
- e189. Flor H, Fydrich T, Turk DC: Efficacy of multidisciplinary pain treatment centers: a meta-analytic review. *Pain* 1992; 49: 221–30.
- e190. Flor H, Turk DC: Chronic pain: an integrated biobehavioral approach. Seattle/WA: IASP Press 2011.
- e191. Heutink M, Post MWM, Bongers-Janssen HMH, et al.: The CONECISI trial: results of a randomized controlled trial of a multidisciplinary cognitive behavioral program for coping with chronic neuropathic pain after spinal cord injury. *Pain* 2012; 153: 120–8.
- e192. Williams ACC, Fisher E, Hearn L, Eccleston C: Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev* 2020; 8: CD007407.
- e193. S3-Leitlinie Langzeitanwendung von Opioiden bei chronischen nicht-tumorbedingten Schmerzen (LONTS). <https://www.awmf.org/leitlinien/detail/ll/145-003.html> (last accessed on 17 August 2022).
- e194. Kwak SG, Choo YJ, Chang MC: Effectiveness of prednisolone in complex regional pain syndrome treatment: a systematic narrative review. *Pain Pract* 2022; 22: 381–90.
- e195. van den Berg C, de Bree PN, Huygen FJPM, Tiemensa J: Glucocorticoid treatment in patients with complex regional pain syndrome: a systematic review. *Eur J Pain* 2022; 26: 2009–35.
- e196. Varena M, Braga V, Gatti D: Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study. *Ther Adv Musculoskelet Dis* 2021; 13: 1759720X211014020.
- e197. van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE: Randomised controlled trial of gabapentin in complex regional pain syndrome type 1. *BMC Neurol* 2014; 4: 13.
- e198. Sigtermans MJ, van Hilten JJ, Bauer MC, et al.: Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. *Pain* 2009; 145: 304–11.
- e199. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M: Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. *Pain* 2009; 147: 107–15.
- e200. Zhao J, Wang Y, Wang D: The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and meta-analysis. *Curr Pain Headache Rep* 2018; 22: 12.
- e201. Kirkpatrick AF, Saghabi A, Yang K, et al.: Optimizing the treatment of CRPS with ketamine. *Clin J Pain* 2020; 36: 516–23.
- e202. Breuer AJ, Mainka T, Hansel N, Maier C, Krumova EK: Short-term treatment with parecoxib for complex regional pain syndrome: a randomized, placebo-controlled double-blind trial. *Pain Physician* 2014; 17: 127–37.
- e203. Fitzcharles MA, Petzke F, Tölle TR, Häuser W: Cannabis-based medicines and medical cannabis in the treatment of nociceptive pain. *Drugs* 2021; 81: 2103–16.
- e204. Almog S, Aharon-Peretz J, Vulfsons S, et al.: The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. *Eur J Pain (United Kingdom)* 2020; 24: 1505–16.
- e205. Maihöfner C, Schneider S, Bialas P, et al.: Successful treatment of complex regional pain syndrome with topical ambroxol: a case series. *Pain Manag* 2018; 8: 427–36.
- e206. Finch PM, Knudsen L, Drummond PD: Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. *Pain* 2009; 146: 18–25.
- e207. Ushida T, Tani T, Kanbara T, Zinchuk VS, Kawasaki M, Yamamoto H: Analgesic effects of ketamine ointment in patients with complex regional pain syndrome type 1. *Reg Anesth Pain Med* 2002; 27: 524–8.
- e208. Russo MA, Santarelli DM: A novel compound analgesic cream (ketamine, pentoxifylline, clonidine, DMSO) for complex regional pain syndrome patients. *Pain Pract* 2016; 16: E14–20.
- e209. NICE: Neuropathic pain in adults: pharmacological management in non-specialist settings. London: NICE, 2013. <https://www.nice.org.uk/guidance/cg173/resources/neuropathic-pain-in-adults-pharmacological-management-in-nonspecialist-settings-pdf-35109750554053> (last accessed on 22 September 2022).
- e210. Finnerup NB, Haroutounian S, Kamerman P, et al.: Neuropathic pain: an updated grading system for research and clinical practice. *Pain* 2016; 157: 1599–606.
- e211. Okumo T, Takayama Y, Maruyama K, Kato M, Sunagawa M: Senso-immunologic prospects for complex regional pain syndrome treatment. *Front Immunol* 2022; 12: 786511.
- e212. Gustin SM, Schwarz A, Birbaumer N, et al.: NMDA-receptor antagonist and morphine decrease CRPS-pain and cerebral pain representation. *Pain* 2010; 151: 69–76.
- e213. Janssen A: Spiegelakupunktur bei komplexem regionalen Schmerzsyndrom (CRPS). *Deutsche Zeitschrift für Akupunktur DZA* 2020; 63: 96–8.
- e214. Bilgili A, Cakir T, Dogan SK, Ercalik T, Filiz MB, Toraman F: The effectiveness of transcutaneous electrical nerve stimulation in the management of patients with complex regional pain syndrome: a randomized, double-blinded, placebo-controlled prospective study. *J Back Musculoskelet Rehabil* 2016; 21: 661–71.
- e215. Li N, Tian F, Wang C, et al.: Therapeutic effect of acupuncture and massage for shoulder-hand syndrome in hemiplegia patients: a clinical two-center randomized controlled trial. *J Tradit Chin Med* 2012; 32: 343–9.
- e216. Korpan MI, Dezu Y, Schneider B, Leitha T, Fialka-Moser V: Acupuncture in the treatment of posttraumatic pain syndrome. *Acta Orthop Belg* 1999; 65: 197–201.
- e217. Wang WY, Wan FM, Ding SQ: [Clinical observation of Jingu three-needle therapy combined with Xingnao Kaiqiao acupuncture on complex regional pain syndrome after stroke]. *Zhongguo Zhen Jiu* 2019; 39: 1262–6.
- e218. S3-Leitlinie „Epidurale Rückenmarkstimulation zur Therapie chronischer Schmerzen“. <https://www.awmf.org/leitlinien/detail/ll/008-023.html> (last accessed on 22 September 2022).
- e219. Deer TR, Levy RM, Kramer J, et al.: Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. *Pain* 2017; 158: 669–81.
- e220. Hoydonckx Y, Costanzi M, Bhatia A: A scoping review of novel spinal cord stimulation modes for complex regional pain syndrome. *Can J Pain* 2019; 3: 33–48.
- e221. Deer TR, Hunter CW, Mehta P, et al.: A systematic literature review of dorsal root ganglion neurostimulation for the treatment of pain. *Pain Med* 2020; 21: 1581–9.
- e222. Levy RM, Mekhail N, Kramer J, et al.: Therapy habituation at 12 months: spinal cord stimulation versus dorsal root ganglion stimulation for complex regional pain syndrome type I and II. *J Pain* 2020; 21: 399–408.
- e223. D'Souza RS, Kubrova E, Her YF et al.: Dorsal root ganglion stimulation for lower extremity neuropathic pain syndromes: an evidence-based literature review. *Adv Ther* 2022; 39: 4440–73.
- e224. Canós-Verdecho A, Abejón D, Robledo R, et al.: Randomized prospective study in patients with complex regional pain syndrome of the upper limb with high-frequency spinal cord stimulation (10-kHz) and low-frequency spinal cord stimulation. *Neuromodulation* 2021; 24: 448–58.
- e225. Eitner L, Vollert J, Maier C, Attal N: Botulinumtoxin-A-Injektionen bei neuropathischem Schmerz: Eine Post-hoc-Subgruppenanalyse bei Patienten mit peripherer Nervenverletzung. *Schmerz* 2017; 31: 524–6.
- e226. Park J, Chung ME: Botulinum toxin for central neuropathic pain. *Toxins (Basel)* 2018; 10: 224.
- e227. van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM: Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. *N Engl J Med* 2000; 343: 625–30.
- e228. van Rijn MA, Munts AG, Marinus J, et al.: Intrathecal baclofen for dystonia of complex regional pain syndrome. *Pain* 2009; 143: 41–7.
- e229. Picarelli H, Teixeira MJ, de Andrade DC, et al.: Repetitive transcranial magnetic stimulation is efficacious as an add-on to pharmacological therapy in complex regional pain syndrome (CRPS) type I. *J Pain* 2010; 11: 1203–10.
- e230. Lagueux É, Bernier M, Bourgault P, et al.: The effectiveness of transcranial direct current stimulation as an add-on modality to graded motor imagery for treatment of complex regional pain syndrome: a randomized proof of concept study. *Clin J Pain* 2018; 34: 145–54.
- e231. Nardone R, Brigo F, Höller Y, et al.: Transcranial magnetic stimulation studies in complex regional pain syndrome type I: a review. *Acta Neurol Scand* 2018; 137: 158–64.
- e232. Kiralp MZ, Yildiz S, Vural D, Keskin I, Ay H, Dursun H: Effectiveness of hyperbaric oxygen therapy in the treatment of complex regional pain syndrome. *J Int Med Res* 2004; 32: 258–62.
- e233. O'Connell NE, Wand BM, Gibson W, Carr DB, Birklein F, Stanton TR: Local anaesthetic sympathetic blockade for complex regional pain syndrome. *Cochrane Database Syst Rev* 2016; 7: CD004598.

- e234. Straube S, Derry S, Moore RA, McQuay HJ: Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. *Cochrane Database Syst Rev* 2010; CD002918.
- e235. Del Piñal F: Outcomes of carpal tunnel release in complex regional pain syndrome/reflex sympathetic dystrophy/sudeck disease patients. *Plast Reconstr Surg* 2022; 150: 93–101.
- e236. Ayyaswamy B, Saeed B, Anand A, Chan L, Shetty V: Quality of life after amputation in patients with advanced complex regional pain syndrome: a systematic review. *EFORT Open Rev* 2019; 4: 533–40.
- e237. Schrier E, Geertzen JHB, Scheper J, Dijkstra PU: Psychosocial factors associated with poor outcomes after amputation for complex regional pain syndrome type-I. *PLoS One* 2019; 14: e0213589.

eBOX

Technical investigations, useful for differential diagnostics of CRPS***Three-phase bone scan with technetium-99m diphosphonate (qualitative evaluation)**

- Normal result does not exclude CRPS
- Possible demonstration of a not very sensitive (31–50%), but specific (77–100%) band-like juxta-articular radionuclide scan uptake
- May support the diagnosis, especially during the first year—but its validity decreases with increasing duration of illness

Conventional X-ray diagnostics and computed tomography (bone density tests)

- Normal result does not exclude CRPS.
- Common, nonspecific asymmetrical juxta-articular patchy osteopenia as compared with the contralateral side, in about one half of CRPS patients after 4–8 weeks, as also seen in other disorders
- Not to be confused with osteoporosis secondary to physical inactivity

Magnetic resonance imaging

- Normal result does not exclude CRPS
- Sometimes, subcutaneous/periarticular contrast uptake and (nonspecific) bone marrow edema/bone bruises
- Occasional demonstration of nerve injury in cases of CRPS 2
- But does not reliably differentiate CRPS, serves instead to exclude some differential diagnoses

Temperature measurement

- Normal result makes CRPS unlikely
- Thermography, infra-red thermometer, thermal imaging camera
- Repeated or long-term measurements in particular reveal temperature differences in comparison with the contralateral side, as well as asynchronous fluctuations and oscillations between left and right side

Quantitative sensory testing (QST)

- Normal result makes CRPS unlikely
- Thermal hypoesthesia, mechanical and thermal hyperalgesia support the diagnosis of CRPS
- Does not reliably distinguish from normal fracture healing, however

Electrophysiology

- Normal result militates against CRPS 2
- In CRPS 2, reduced amplitude and/or reduced nerve conduction velocity in motor/sensory nerve conduction studies; signs and symptoms, however, do not correspond to a definite nerve distribution
- Occasionally nonspecific abnormalities in CRPS 1
- Caution: strict indication essential for needle electromyography

Laboratory tests (blood, skin biopsy, and the like)

- No reliable CRPS marker available to date
- Normal result militates in favor of CRPS
- Elevated serum osteoprotegerin (osteoblast activity marker) may reveal increased bone turnover during the first six months just as well as a bone scan.

*Given the wide-ranging differential diagnosis, only the most important procedures are presented here. CRPS, complex regional pain syndrome

eTABLE 1

Pharmacotherapy of complex regional pain syndrome (CRPS)

Substance class	Mode of application and primary mode of action	Comments	CRPS-LL ^{*1}
Bisphosphonates	PO, IV, IM Osteoclast inhibitory, anti-inflammatory, immunomodulatory effects	<ul style="list-style-type: none"> ● seven RCTs ● in the acute phase, when duration of illness <12 months ● poor oral absorption, tolerability and risk profile unfavorable with IV administration (caution: osteonecrosis of the jaw) ● no potential for addiction 	+
Glucocorticoids	PO Anti-inflammatory, as well as immunomodulatory and analgesic	<ul style="list-style-type: none"> ● two RCTs ● in the acute phase, as early as possible within the first six months ● extracorporeal shock wave therapy for two weeks, not for maintenance therapy ● effects evident possibly within three weeks ● relatively few side effects, no potential for addiction 	+
Gabapentinoids	PO Central, probably also peripheral, pain modulation	<ul style="list-style-type: none"> ● one RCT on gabapentin: poor effect; better effect on disturbances of sensory function than on pain ● effective against neuropathic (in some cases of CRPS 2), possibly also against nociceptive pain ● only case report to date on pregabalin in children, no RCT; nevertheless, surprisingly uncritical prescription ● gabapentin and pregabalin approved, and first-choice drug, for neuropathic pain^{*2} ● caution: potential for addiction to pregabalin; guideline warning regarding use for neuropathic pain in patients with comorbid addiction^{*2} 	(+)/(–)
Tri-/tetracyclic antidepressants	PO Central pain modulation	<ul style="list-style-type: none"> ● evening dose utilizes sedative effect; otherwise, relatively unfavorable side effects ● low dose is usually adequate but is usually insufficient for the treatment of comorbid depression ● no potential for addiction ● first choice for neuropathic pain^{*2} ● amitriptyline is approved for neuropathic pain ● caution: combination of amitriptyline with a CYP2D6 inhibitor (especially duloxetine)^{*1} 	NM
Serotonin noradrenalin reuptake inhibitors	PO Central pain modulation	<ul style="list-style-type: none"> ● possible synergistic improvement of pain, motivational drive, and mood in cases of comorbid anxiety disorder/depression ● drive-enhancing effect, usually to be taken in the morning ● no potential for addiction ● SSRI: negative recommendation for neuropathic pain^{*2} ● SNRI: only duloxetine (approved for diabetic polyneuropathy) is recommended as drug of first choice, weak recommendation for venlafaxine^{*2} ● caution: combination of a CYP2D6 inhibitor (especially duloxetine) with amitriptyline^{*1} 	NM
Ketamine	IV Central neuroplastic, neuro- and pain modulation	<ul style="list-style-type: none"> ● two RCTs ● good, rapid, but only short-lasting analgesia ● many risks; caution: addiction, intoxication, angina pectoris, increased heart rate and blood pressure, organ toxicity ● individually titrated, single continuous infusion under inpatient conditions in intractable cases ● requires strict indication, including thorough evaluation of mental comorbidities and continuous monitoring in specialist centers ● negative recommendation for neuropathic pain^{*2} 	(+)
Opioids	PO Central analgesic	<ul style="list-style-type: none"> ● mainly preventive and in the acute phase ● longer-term therapeutic use only in case of positive effect and few or tolerable side effects^{*3} ● are viewed with increasing skepticism; caution: addiction, opioid-induced hyperalgesia, sedation, sleep disturbances ● third choice treatment for neuropathic pain^{*1} ● possible advantage of tramadol (proven for neuropathic pain)/tapentadol (assumed): μ-opioid receptor agonism and noradrenergic/serotonergic reuptake inhibition 	NM
Non-steroidal anti-inflammatory drugs, COX-2 inhibitors	PO Peripheral analgesic, anti-inflammatory	<ul style="list-style-type: none"> ● two RCTs ● preventative measure after injuries/surgery, in particular, possibly also in the acute phase ● efficacy in CRPS not proven ● negative recommendation for neuropathic pain^{*1} 	NM
Botulinum toxin A	IM/SC Reduces muscle contraction/ sweating; probably also has a local analgesic effect	<ul style="list-style-type: none"> ● third choice (SC) for focal neuropathic pain^{*1} ● according to CRPS guideline, option (IM) for treatment-limiting focal dystonia, but with no clear recommendation 	(+)

Cannabinoids	PO/SL Central pain modulation	<ul style="list-style-type: none"> off-label third-line treatment attempt with oral cannabis extracts when other pain treatments have failed after submitting an application pursuant to section 31 subsection 6 German Social Security Code (SGB) Part V caution: sedation/adynamia, enhanced anxiety, psychoses considering its minimal effect and high side-effect rate, no recommendation for neuropathic pain^{*1} 	NM
N-acetylcysteine (NAC)	PO Free radical scavenger	<ul style="list-style-type: none"> one RCT treatment attempt for cold CRPS 	(+)
Dimethyl sulfoxide (DMSO) – ointment	Topical Free radical scavenger	<ul style="list-style-type: none"> one RCT standard therapy in the Netherlands 	(-)
5% lidocaine patch	Topical Local analgesic	<ul style="list-style-type: none"> second choice for neuropathic pain^{*2}, especially recommended for focal nerve injury due to its lower side effects rate^{*2} 	NM
20% ambroxol cream	Topical Local analgesic	<ul style="list-style-type: none"> initial data encouraging 	NM
8% capsaicin patch	Topical Local analgesic	<ul style="list-style-type: none"> early use recommended must be applied and removed by qualified medical staff duration of action around 12 weeks after single application for one hour for neuropathic pain/allodynia in particular approved for neuropathic pain secondary to CRPS second choice for neuropathic pain^{*2}, but preferably used for focal nerve injury because of its lower side effects rate^{*2} 	NM
10% ketamine cream	Topical Local analgesic	<ul style="list-style-type: none"> initial data encouraging 	NM

^{*1} according to CRPS guideline weak recommendation +; recommendation with restrictions (+); no recommendation -; data too unclear: (-); NM not mentioned

^{*2} according to S2k guideline "Diagnosis and Non-Interventional Treatment of Neuropathic Pain"

^{*3} according to S3 guideline "Long-term Administration of Opioids for Non-tumor Pain (LONTS)"

CRPS, complex regional pain syndrome; CRPS-LL, S1 guideline "Diagnostic and Treatment Guidelines for Complex Regional Pain Syndrome"; IM: intramuscular; IV: intravenous; PO, oral; RCT, randomized controlled trial; SL: sublingual; SNRI, serotonin noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor;

eTABLE 2

Technical or invasive interventions for complex regional pain syndrome (CRPS)

Procedure	Mode of application	Comments	CRPS-LL* ¹
Dorsal root ganglion (DRG) stimulation	Not local, invasive	<ul style="list-style-type: none"> ● one controlled study ● possible alternative to SCS: longer pain relief and fewer side effects ● only in patients with no significant mental comorbidity ● after successful test stimulation 	(+)
Spinal cord stimulation (SCS)	Not local, invasive	<ul style="list-style-type: none"> ● one RCT ● in CRPS of the lower limb without mechanical allodynia and without significant mental comorbidity ● after successful test stimulation ● S3 guideline on spinal cord stimulation: weak recommendation for CRPS 1, "open" recommendation for CRPS 2*² 	(+)
Intrathecal baclofen	Not local, invasive	<ul style="list-style-type: none"> ● one small RCT, one controlled study ● high complication rate, e.g. infection, low cerebrospinal fluid pressure syndrome, urinary retention ● painful and treatment-limiting dystonia not manageable by conservative treatment ● only in patients with no significant mental comorbidity; consider an underlying functional cause in intractable cases (or with an immediate effect) ● reserved for specialist centers ● test injection prior to maintenance therapy 	(+)
Sympathetic trunk block	Not local, invasive	<ul style="list-style-type: none"> ● three RCTs ● for intractable confirmed sympathetically maintained pain (SMP) 10(–15) blocks (SMP clinically, difficult to differentiate) ● reserved for specialist centers ● caution: risks, above all: infection, neurovascular injury – no serial injections without significant improvement 	(+)
Repetitive transcranial magnetic stimulation	Not local, not invasive	<ul style="list-style-type: none"> ● one RCT ● reduces pain possibly for some days by modifying central pain processing ● caution: epilepsy is a contraindication ● may be tried in individual intractable cases 	(+)
Plasmapheresis	Not local, invasive	<ul style="list-style-type: none"> ● no RCT ● caution: risks, above all infections, clotting abnormalities 	(-)
Sympathectomy/sympathetic nerve ablation	Not local, destructive	<ul style="list-style-type: none"> ● caution: high risk of deafferentation pain/neuralgia and motor function deterioration 	(-)
Various pain catheters	Not local, invasive	<ul style="list-style-type: none"> ● no RCT, only case reports using various substances, e.g. local anesthetics, clonidine ● caution: risks, above all infections, neurovascular injury 	NM
Hyperbaric (100%) oxygen therapy	Not local, invasive	<ul style="list-style-type: none"> ● one RCT ● uncertain benefit-risk ratio 	NM
Various surgical procedures for findings worthy of surgery	Local invasive	<ul style="list-style-type: none"> ● e.g. joint stabilization or nerve decompression ● dilemma: local procedures (and hence renewed traumatic injury) usually aggravate signs and symptoms. However, symptomatic recovery is sometimes achieved in isolated cases by surgical removal of local painful/inflammatory stimuli or by improved perfusion/innervation, above all when nerve compression has resulted in CRPS 2. 	NM
Amputation	Local destructive	<ul style="list-style-type: none"> ● last resort in rare individual cases ● caution: high risk of clinical (e.g. deafferentation pain) and functional deterioration ● caution: mental comorbidity, above all factitious and body integrity identity disorders 	NM

*¹ According to S1 guideline "Diagnostics and Treatment of complex regional pain syndrome (CRPS)": recommendation with restrictions: (+); available data too uncertain: (-); not mentioned: NM

*² According to S3 guideline "Epidural Spinal Cord Stimulation for Treatment of Chronic Pain"

CRPS, complex regional pain syndrome; CRPS-LL, S1 guideline "Diagnostics and Therapy of Complex Regional Pain Syndrome"; DRG, dorsal root ganglion; RCT, randomized controlled trial; SCS, spinal cord stimulation

Questions on the article in issue 51–52/2022:

Modern Principles of Diagnosis and Treatment in Complex Regional Pain Syndrome

cme plus+

The submission deadline is 26 December 2023. Only one answer is possible per question. Please select the answer that is most appropriate.

Question 1

What are risk factors for developing CRPS?

- a) prolonged immobilization, high initial pain intensity, female sex
- b) mobilization encouraged too early, depression, male sex
- c) infectious diseases, reduced general condition, advanced age
- d) history of addiction, heavy physical work, migration background
- e) ADHD, unemployment, adolescence

Question 2

What is meant in the article by the term nociplastic pain?

- a) potentially reversible pain after plastic surgery
- b) pain due to potentially reversible central hypersensitivity to stimuli without tissue or nerve damage
- c) pain due to irreversible central hyposensitivity to stimuli with tissue damage
- d) potentially reversible delusional pain associated with neoplasm
- e) irreversible pain due to toxic nociceptive stimulation

Question 3

A 63-year-old worried female patient presents for follow-up to confirm maintained reduction of a distal radius fracture managed conservatively. What do you discuss with her?

- a) That complications during the course of healing are likely due to her age
- b) That she must expect continuing pain
- c) That she does not need to consult a doctor again, even if she notices unusual signs and symptoms such as changes in skin color, in nail or hair growth
- d) That she should touch the fingers of the affected hand as normally as possible and carefully move them
- e) That she should take medication to treat her anxiety

Question 4

Which symptoms commonly occur with CRPS but are not yet included in the diagnostic criteria?

- a) lack of appetite, weight loss, night sweats
- b) body perception disturbance, e.g., experiencing the affected limb as alienated
- c) mood fluctuations, self-harm tendencies, ligature marks
- d) crepitations or air inclusions in tissue
- e) exhaustion, abscess formation, fever

Question 5

How is the diagnosis of CRPS confirmed or excluded?

- a) The diagnosis of CRPS is excluded by normal findings on X-ray in comparison with the healthy side.
- b) A bone scan is required to confirm the diagnosis of CRPS.
- c) CRPS is a clinical-interdisciplinary diagnosis confirmed according to the Budapest criteria.
- d) Evidence of nerve damage is required for the diagnosis of CRPS.
- e) The diagnosis of CRPS is confirmed by quantitative sensory testing.

Question 6

What is the treatment of CRPS?

- a) A predominantly surgical approach by joint release, tenolysis and/or neurolysis
- b) A predominantly passive-analgesic approach using the WHO Analgesic Ladder
- c) A predominantly interdisciplinary approach using rehabilitation and pain medication
- d) A predominantly psychotherapeutic approach applying the principles of depth psychology
- e) As time-saving and cost-reducing as possible because treatment is usually unsuccessful

Question 7

What is “graded exposure” in physiotherapy and occupational therapy of CRPS?

- a) Gradual stepwise approach to the accident location with psychological support
- b) Passive mobilization of the affected limb several times a day
- c) Gradual, stepwise, motor and sensory exercises with psychological support
- d) Exposure to the pain without psychological support
- e) Staged dosing of analgesics

Question 8

What are the core elements of graded motor imagery?

- a) Massage, manual lymph drainage, continuous passive motion machine
- b) Adequate immobilization, then mobilization under anesthesia
- c) Opioid titration, passive physiotherapy, then opioid withdrawal
- d) Confrontation with images of severe CRPS cases on the computer or using VR eyeglasses.
- e) Left-right discrimination training, explicit motor imagery, mirror therapy

Question 9

How can the typical signs of inflammation in patients with early CRPS (swelling, redness, increased warmth) be alleviated?

- a) Bisphosphonates or steroids, manual lymph drainage
- b) Steroid injection into the affected joints, strict immobilization
- c) Shock wave therapy under sedation, possibly under hypnosis
- d) Lidocaine patch, if ineffective then fentanyl or buprenorphine patches
- e) Antibiotic treatment based on antibiogram

Question 10

Which groups of substances are suitable for symptomatic medical management of the neuropathic pain components of CRPS?

- a) Steroids
- b) Antidepressants and antiepileptic drugs/gabapentinoids
- c) Bisphosphonates
- d) NSAR
- e) Ketamine